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Abstract 
 
Objective: Extremes of fetal growth are associated with increased perinatal mortality and 
morbidity and a higher prevalence of cardiovascular disease, obesity and diabetes in later life. 
The placenta plays a pivotal role in fetal growth and development. We aimed to identify 
changes in placental gene expression in term pregnancies with evidence of growth 
dysfunction and to identify candidate genes that may be used to identify abnormal patterns of 
growth prior to delivery. 
 
Materials and methods: Placenta samples were collected and classified from pregnancies 
that affected by fetal growth restriction (birth weight <10
th
 percentile; n=4), macrosomia 
(birth weight >90
th
 percentile; n=6) or normal pregnancies (birth weight between 40
th
 and 60
th
 
percentile; n=5). All pregnancies were 39 weeks’ gestation, with male infants delivered by 
Caesarean section. RNA was extracted from the placental samples prior to microarray gene 
expression analysis using Affymetrix HG-U219 array strip kits. Microarray data were 
analysed using Partek Express, Ingenuity Pathway Analysis software, Visualization and 
Integrated Discovery (DAVID) online tool, and Protein ANalysis THrough Evolutionary 
Relationships (PANTHER) online tool. Significant differential gene expression was defined 
by >2 fold-change with p<0.05. 
 
Results: Significant changes in gene expression between fetal growth restriction and control 
samples were seen with 242 transcripts (representing 199 genes) up-regulated and 191 
transcripts (139 genes) down-regulated. Fewer significant changes were found when 
comparing macrosomic and control specimens with 42 transcripts (representing 33 genes) and 
10 transcripts (representing 8 genes) being up-regulated and down-regulated respectively. 
V 
 
Potential biomarkers for fetal growth restriction including TXNDC5, LRRFIP1, LRP2, 
ENPEP, PPFIBP1, CPXM2, CLDN1, ST3GAL1, TRPV6, and CD200 were identified. In 
macrosomic newborns leptin with 6.5 fold-change down-regulation (p=0.01) together with 
COL17A1, GCH1, PHLDB2, KATNBL1, CLDN1, and LPHN3 were candidate genes as 
biomarkers. 
 
Conclusions: Dysfunctional growth is associated with differential placental gene expression 
and affects genes involved with a whole spectrum of developmental and cellular functions. In 
fetal growth restriction, important pathways with wide range of functions including 
embryonic development, angiogenesis, amino acids metabolism, transmembrane transport of 
small molecules, Notch signalling, and p53 signalling pathway were identified, indicating the 
complex pathophysiology of the fetal growth restriction. Leptin which plays a crucial role in 
energy homeostasis and control of food intake appears to be decreased in macrosomic 
newborns and might be of significance for long term outcome. 
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Chapter 1  
Placental development and physiology 
1.1. Introduction 
The name ‘placenta’ derives from the Greek word ‘plakuos’ which means ‘flat cake’. The 
placenta is the interface between the mother and the fetus and regulates the amount and 
composition of nutrients transported. It is a haemochorial, villous type organ where the 
maternal blood enters the intervillous space via the spiral arteries and flows directly around 
the terminal villi of the fetal circulation without any intervening maternal vessel wall 
(Haggarty, 2005). The chorioallantoic placenta is the defining organ of eutherians that has 
enabled prolonged intrauterine gestation. As such, normal placental development and function 
are essential for mammalian reproductive success. The characteristic cell type that forms 
substantial parts of the placenta is called the ‘trophoblast’ (from Greek trephein ‘to feed’ and 
blastos ‘germinator’). In addition to regulating nutrient supply, the placenta also has a number 
of other pivotal functions highlighting the importance of normal trophoblast differentiation in 
ensuring a successful pregnancy (John and Hemberger, 2012). The earliest trophoblast cells, 
which differentiate into various placental cell types, are under tight genetic and epigenetic 
control (Fowden et al., 2011). 
 
Varying degrees of abnormal placental development and secondary pathological processes 
underpin complications of pregnancy (Chaddha et al., 2004). Failure of one or more key 
components of placentation may result in a wide range of complications for the mother and/or 
the fetus, including embryonic and second-trimester fetal death, preeclampsia, fetal growth 
restriction (FGR) and abruption (Chelbi and Vaiman, 2008). 
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1.2. Development of the placenta 
Placentation is a multi-step process which begins with implantation of the blastocyst into the 
uterine tissue. The placenta is composed of fetal and maternal components; the fetal part 
consists of trophoblast and extraembryonic mesoderm (chorionic plate) while the 
endometrium gives rise to the maternal part. Approximately three to four days after 
fertilization, the morula enters the uterus and a cavity appears within the cell mass forming 
the blastocyst. The inner cell mass differentiates into the tissues of the embryo. The 
surrounding epithelial cells, the trophectoderm, give rise to the placenta. Six to seven days 
after conception, while the endometrium is in the secretory phase, the microvilli on the 
trophoblastic cells begin to interact with the microvilli of pinocytes on the endometrial cells. 
Meanwhile, decidualization takes place in the endometrium which includes secretory 
alteration of the endothelial gland, inflow of specialised uterine natural killer cells, and 
vascular remodelling. This process is largely controlled by the ovarian hormones oestrogen 
and progesterone. Finally, trophoblast cells, influenced by matrix metalloproteinases, invade 
the decidua and the trophectoderm differentiates into the cytotrophoblast. The invasion 
process involves vascular remodelling of the placental bed controlled by variety of molecules 
and maternal endocrine signals. These changes promote blood flow to the implantation site 
and mediate the maternal adaptive responses to pregnancy. This final human-specific step 
leads to the formation of a haemochorial placenta at the end of the first trimester (Chaddha et 
al., 2004, Chelbi and Vaiman, 2008). 
 
During placentation, cytotrophoblasts fuse together to form the multinucleated 
syncytiotrophoblast which is responsible for secretion of human chorionic gonadotropin 
(hCG) and progesterone; hormones necessary for the continuation of pregnancy. The 
syncytiotrophoblast also delivers oxygen and nutrients to the fetus and removes waste from it. 
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The proximal columns of cytotrophoblast are penetrated centrally by mesodermal cells and 
consequently haemangioblasts enter and fetoplacental blood vessels form by vasculogenesis 
(Chaddha et al., 2004). Morphologically, the outermost layer of villi is formed from the 
syncytiotrophoblast overlying cytotrophoblastic cells that cover a core of vascular mesoderm. 
Cytotrophoblasts that penetrates beyond the syncytiotrophoblast shell contribute to the 
formation of the extravillous cytotrophoblast. Vacuolar spaces begin to appear within the 
mantle and steadily these spaces come together to constitute larger lacunae which develop to 
the intervillous space. Expansion of lacunae reduces the thickness of the syncytiotrophoblast 
and results in the formation of trabeculae. As cytotrophoblasts reach the distal part of 
trabeculae, the cells begin to spread latterly and make connection with those from other 
trabeculae to form the cytotrophoblastic shell. 
 
By 20 weeks’ gestation, large numbers of decidual septa with a maternal core grow into the 
intervillous space without touching the chorionic plate. However, these decidual septa rest in 
a layer of syncytial cells. As a result of septal formation, macroscopic compartments appear in 
the placenta called cotyledons. Approximately 100 spiral arteries pass through the cotyledons 
and penetrate the decidual plate and supply blood to the intervillous spaces. A term placenta is 
characterised by its discoid shape measuring approximately 15 to 25 cm in diameter, 3cm in 
thickness, and 500 - 600 gm in weight. 
 
1.3. The roles of the placenta 
In mammals, placental function is the cornerstone of reproductive success playing a pivotal 
role in fetal growth and developmental programming. The birth of a healthy infant at term 
requires a coordinated series of events ensuring the normal development of both embryo and 
placenta. To achieve this goal, the placenta must integrate signals from the fetus and the 
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mother in order to match fetal demand with maternal substrate supply. At the same time the 
placenta must meet its own high metabolic demands, while also enabling excretion of various 
metabolites and carbon dioxide (Chaddha et al., 2004, Roland et al., 2012). The placenta 
mediates the active transport of nutrients and metabolic waste across the barrier separating the 
maternal and fetal compartments, and modifies the composition of some nutrients through its 
own metabolic activity (Garnica and Chan, 1996). It also synthesizes a wide range of 
structural proteins and enzymes and a range of products with putative endocrine, metabolic, 
haemostatic and immunological functions (Carter, 2000). The placenta also plays a role in the 
exposure of the fetus to potentially toxic xenobiotics via the maternal circulation (Prouillac 
and Lecoeur, 2010). 
 
Changes in both the gross morphology and ultrastructure of the placenta occur with increasing 
gestational age in response to nutritional and endocrine manipulations (Sibley et al., 1997, 
Sibley et al., 2005). These changes lead to alterations in vascularity and the surface area 
available for exchange of factors. The thickness of the interhaemal membrane and the density 
of transporter proteins also affect placental transport efficacy (Burton and Fowden, 2012). 
Coordinated development of the fetal villous tree and the vasculature of the placenta are 
therefore necessary for normal fetal growth and well-being. Blood vessels develop by 
branching angiogenesis growing into immature intermediate villi and then forming large 
numbers of gas-exchanging terminal villi. This process involves non-branching angiogenesis 
in mature intermediate villi (Kingdom et al., 2000). 
 
Another role of the placenta is providing a low oxygen environment to ensure the protection 
of the fetus from free oxygen radicals in the first trimester. The early embryo and developing 
placental villi are vulnerable to oxygen-mediated injury (Rodesch et al., 1992, Jauniaux et al., 
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2000). The occlusion of the tips of the spiral arteries by plugs of endovascular trophoblast 
cells occurs in during the first 10 to 12 gestational weeks. Maternal blood flow does not occur 
within the intervillous space during this time, resulting in an oxygen poor environment which 
is important for the developing embryo. Non-physiological levels of oxygen tension in the 
first trimester may impair metabolism and cause tissue damage (Hustin and Schaaps, 1987, 
Hempstock et al., 2003). An abnormal increase in intervillous circulation has been proposed 
to cause miscarriage (Merce et al., 2009). From the sixth gestational week onwards maternal 
intervillous blood flow occurs with a gradual increase during the first trimester (Merce et al., 
2009). 
  
Aspects of placental function can be divided into three main components: (i) transfer of 
nutrients and waste products, (ii) a metabolic role with endocrine functions, and (iii) 
immunologic functions. 
 
1.3.1. Nutrient transfer and metabolic role 
In mammals, the major determinant of intrauterine growth is the placental nutrient supply, 
which, in turn, depends on the size, morphology, blood supply, and transporter abundance of 
the placenta. It also depends on the synthesis and metabolism of nutrients and hormones in the 
uteroplacental tissues (Fowden et al., 2006). In the second and third trimesters, the noticeable 
expansion of the placenta through the proliferation of different cell types maintains the high 
level of nutrient supply. The nutrients are basically used for the purposes of generating 
cellular energy, synthesizing DNA and RNA, proteins, membranes, and other components 
crucial for cellular growth. Simple diffusion, facilitated diffusion, active transport and 
receptor-mediated endocytosis are the common pathways for nutrient transfer across the 
placenta. 
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The syncytiotrophoblast and the fetal capillary endothelium express transporters (Vahakangas 
and Myllynen, 2009). In syncytiotrophoblast, various transporters have been found both in the 
brush-border (apical membrane) facing maternal blood and in the basolateral membrane close 
to fetal capillaries where they transfer compounds in and out of the syncytiotrophoblast 
(Vähäkangas and Myllynen, 2009). 
 
In order to warrant the demand of the growing fetus, complex interactions between the 
developing microvillous and basal membrane within the trophoblast and between the maternal 
and fetal circulations occur to facilitate an increase in nutrient delivery (Regnault et al., 2005). 
The placenta is a metabolically active interface and has a dynamic regulatory function, 
sensing the concentration of available nutrients (Jansson and Powell, 2006). The placenta 
adapts to increase its transport capacity under conditions when the maternal nutrient supply or 
placental size may be limiting for normal fetal growth (Burton and Fowden, 2012). Placental 
transporters are subjected to regulation by hormones. For example, insulin up-regulates 
several key placental transporters and maternal insulin may represent a ‘good nutrition’ signal 
to increase placental nutrient transfer and the growth of the fetus (Jansson and Powell, 2006). 
The placenta is thus an active and crucial partner with both the fetus and mother in 
determining fetal growth. 
 
Various factors affect nutrient transfer across the syncytiotrophoblast. These include: (1) 
maternal and fetal blood flow; (2) the nutrient concentration gradient across the 
syncytiotrophoblast; (3) the concentration of transporter proteins to facilitate or actively 
transport nutrients; (4) the exchangeable surface area; (5) the rate of diffusion of some 
nutrients across membranes without the intervention of transport proteins; (6) metabolism 
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(utilization and de novo synthesis) within the placenta; and (7) the rate of nutrient utilization 
by the fetal tissues (Haggarty, 2005). 
 
Many of the common pregnancy pathologies are associated with abnormalities in the transport 
and metabolism of important compounds such as glucose, oxygen, and amino acids. 
 
1.3.1.1. Oxygen metabolism 
The placenta has a high rate of oxygen consumption and despite low intervillous partial 
pressure of oxygen (pO2), about 40% cent of total uterine oxygen uptake is consumed by the 
placenta (Bonds et al., 1986). Most of the oxygen consumption in the placenta is likely to be 
used for oxidative phosphorylation. Protein synthesis also accounts for a substantial fraction 
of placental oxygen consumption, as in vitro experiments have revealed that at physiological 
pO2, placenta has a protein synthesis rate of 40% per day (Carroll and Young, 1987). Cation 
transport such as the Na
+
/K
+
-pump and Calcium (Ca
2+
)-ATPase makes also a significant 
contribution to placental oxygen consumption (Clausen et al., 1991, Rolfe and Brown, 1997). 
Phosphoenolpyruvate carboxykinase activity and probably glucose production are the other 
important reactions that consume oxygen in the placenta (Diamant et al., 1975, Prendergast et 
al., 1999). These functions are cut back when the oxygen supply is reduced, perhaps in favour 
of preserving structural integrity (Schneider, 2000). 
 
Reduced fetoplacental oxygenation is an underlying cause of pregnancy pathologies, 
including FGR and preeclampsia, which are more common at high altitude because of the 
chronic hypoxia in these areas (Zamudio et al., 2010). The prevalence of low birth weight 
infants is higher among the women who live at high altitudes (Jensen and Moore, 1997, Julian 
et al., 2008). 
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In mammals, the primary transcriptional response to hypoxic stress is mediated by the 
hypoxia-inducible factors (HIFs). oxygen deprivation leads to the up-regulation of genes 
mainly by the HIFs (Majmundar et al., 2010). Under conditions of reduced oxygen supply 
such as those occurring in preeclampsia or FGR, hypoxia responses will be activated in the 
placenta. 
 
1.3.1.2. Glucose metabolism 
Glucose is the primary substrate for fetal growth, a source of carbon skeletons for synthetic 
purposes, and the only one that can be metabolised anaerobically (Zamudio et al., 2010). A 
complex set of mechanisms is involved in maintaining the relatively constant glucose supply 
to the fetus. The facilitated-diffusion glucose transporters (GLUT) family regulates glucose 
uptake into fetal tissue. GLUT1 is embedded in both the microvillus and basal membranes of 
the syncytiotrophoblast (Barros et al., 1995) and GLUT3 and GLUT4 are present on the 
vascular endothelium and the intervillous stromal cells, respectively (Jansson et al., 1995, 
Xing et al., 1998). Immunoblotting and immunocytochemistry experiments have failed to 
detect GLUT2 protein in placental homogenates, microvillous or basal membranes (Jansson et 
al., 1995). Although the fetus has the potential for gluconeogenesis, the actual formation of 
glucose from pyruvate is not apparent until after birth because the rate limiting enzyme 
phosphoenolpyruvate carboxykinase appears only after birth in the immediate newborn 
period. Therefore, the maternal circulation is the only verified source for fetoplacental glucose 
during pregnancy (Kalhan and Parimi, 2000). Glucose is mainly metabolised via the 
glycolytic pathway in the placenta, however glycogen synthesis and pentose pathways have 
also been described in placenta (Moe et al., 1991, Hahn et al., 2001). The human placenta at 
term is thought to be capable of glucose production since glucose-6-phosphatase (G6Pase; 
present in the placenta), is required for the final step in the synthesis of glucose (Prendergast 
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et al., 1999). However, G6Pase in the placenta may be the product of a different gene from 
conventional hepatic G6Pase (Leonce et al., 2006). 
 
Oxidative and non-oxidative fetal glucose metabolism is dependent on the additive effects of 
fetal plasma glucose and insulin concentrations, although there is little effect of basal insulin 
concentration on this metabolism. Glucose-stimulated insulin secretion increases over 
gestation, can be down-regulated by constant, high concentrations of glucose, but enhanced 
by pulsatile hyperglycemia (Hay, 2006). 
 
1.3.1.3. Amino acids metabolism 
During pregnancy, amino acids are essential for the development of the fetus as they are the 
components of proteins and are vital precursors for the synthesis of non-protein substances, 
such as nitric oxide, polyamines, neurotrasmitters, purine and pirimidine nucleotides (Grillo et 
al., 2008). 
  
The transport of amino acids across the placenta is a complex process mediated by 
transporters located on the microvillus plasma membrane and basal membrane of the 
syncytiotrophoblast (Cleal and Lewis, 2008, Grillo et al., 2008, Avagliano et al., 2012). Two 
main classes of amino acid transporters are Na
+
-dependent systems and Na
+
-independent 
systems. Na
+
-dependent transporters include: system A, ASC, N, XGA, β, B
0,+
, and GLY. 
Cationic amino acid transport systems such as y
+
 and glycoprotein associated transport 
systems involving ASC, b
0,+
, L, y
+
L, Xc¯, and T are also described (Grillo et al., 2008). 
 
Na
+
-dependent transport systems have a crucial role in the microvillus plasma membrane 
leading to increased concentrations of amino acids within the cell that require energy to act 
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against the concentration gradient. In contrast, Na
+
-independent systems are essential in the 
outflux of amino acids across the basal membrane (Avagliano et al., 2012). 
 
The genes encoding the different transporters are divided into different solute carrier (SLC) 
families (Desforges and Sibley, 2010). For example, SLC38 encodes systems A and N and the 
Na
+
-coupled neutral amino acid transporter family and SLC43 encodes the Na
+
-independent, 
system-L-like amino acid transporter family (Hediger et al., 2004). 
 
All amino acids, except tryptophan, are present in at least 186% higher concentrations in the 
intervillous space than in maternal venous blood (Camelo et al., 2004). For many amino acids 
the concentration is higher within the placenta than the fetal circulation (Philipps et al., 1978). 
The difference in concentration of amino acids between the intervillous space and maternal or 
fetal circulations suggests active transport of amino acids across the microvillus plasma 
membrane. The placenta therefore plays an active role in determining the flux of amino acids 
into the fetal circulation (Avagliano et al., 2012). 
 
1.3.1.4. Lipid metabolism 
Maternal plasma lipoproteins can be taken up by the placenta via lipoprotein or other 
scavenger receptors. Lipoprotein triglycerides may also be hydrolysed by placental lipases, 
mainly lipoprotein lipase, localised in the microvillous membrane (MVM) (Lindegaard et al., 
2005). Free fatty acids are released by this process and diffuse across the plasma membrane. 
Transfer of non-esterified fatty acids is facilitated by a transporter-mediated mechanism 
involving plasma membrane fatty acid binding proteins, fatty acid translocase, and a family of 
fatty acid transport proteins (Haggarty et al., 2002). 
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1.3.2. Endocrine role 
A special role of the placenta is the neuroendocrine function producing a wide range of 
hypothalamic, pituitary, and end organ analogues. Numerous physiological changes in the 
mother are required to facilitate fetal growth, parturition, lactation and maternal behaviour. 
Hormonal fluctuations in pregnancy are the main reason for these maternal adaptations which 
include changes in brain function and are essential to ensure a successful pregnancy outcome 
(Russell et al., 2001). Indeed, dysregulated placental hormone secretion can lead to FGR. 
These products act as endocrine, paracrine and autocrine factors to control the secretion of 
other regulatory molecules, including the pituitary hormones of both mother and fetus and 
their placental counterparts. Furthermore, they contribute to the regulation of maternal and 
fetal physiology during pregnancy, ranging from the control of placental development to fetal 
growth and maturation, regulation of uterine blood flow and initiation of labor (Reis et al., 
2001). 
 
Cytotrophoblasts and the syncytiotrophoblast are the main sources of synthesis and secretion 
of many placental hormones during pregnancy (Nelson et al., 1986, Kovalevskaya et al., 
2002). Villous stromal cells and Hofbauer cells (placental macrophages that are present in the 
villus across gestation) are also a source of hormones and growth factors (Tang et al., 2011). 
Most placental hormones are protein hormones, but oestrogen and progesterone are steroid 
hormones. Placental proteins have taken a new role in recent years as screening tests for the 
prenatal diagnosis of fetal aneuploidy. Placental proteins are secreted primarily into the 
maternal circulation and their effects are probably confined to the mother (Sorensen et al., 
1995). 
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Hormones that regulate maternal metabolism and fetal growth include human placental 
lactogen (hPL), prolactin (PRL), human placental growth hormone (hPGH), growth hormone 
releasing hormone (GHRH), parathyroid hormone-related protein (PTH-rP), adipocytokines, 
and insulin-like growth factors (IGF). Other hormones secreted by the placenta serve a wide 
range of functions. Some target maternal reproductive organs like hCG, oestrogen, 
progesterone, gonadotropin releasing hormone (GnRH), oxytocin, inhibin A, activin A, and 
follistatin. Corticotropin releasing hormone, urocortin, and adrenocorticotropin regulate stress 
response and vascular endothelial growth factor regulates vascular development. Below some 
of these hormones have been discussed in more detail: 
 
1.3.2.1. Human placental lactogen (hPL) 
hPL is structurally and functionally similar to human growth hormone (GH) and PRL, which 
acts in a prolactin-like manner on PRL receptor on neuroendocrine dopaminergic neurones to 
stimulate dopamine synthesis and release, thus inhibiting PRL secretion from the maternal 
pituitary gland (Freemark, 2006, Grattan et al., 2008). 
 
hPL and PRL might serve an adaptive role in nutrient homeostasis and stimulating maternal 
food intake in pregnancy by induction of central leptin resistance and promoting maternal 
pancreatic beta-cell proliferation and insulin production to defend against the development of 
gestational diabetes mellitus (Newbern and Freemark, 2011). Lactogen signalling through the 
PRL receptor is essential for the establishment and maintenance of beta cell reserve and the 
pancreatic adaptation to maternal insulin resistance which is caused by placental GH in order 
to mobilise maternal nutrients for fetal growth. PRL and hPL also act in concert with 
placental PTH-rP to stimulate gastrointestinal Ca
2+
 absorption, which increases two folds 
during pregnancy (Freemark, 2006). 
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1.3.2.2. Human placental growth hormone (hPGH) 
The syncytiotrophoblast layer of the human placenta produces a GH specific to this organ. 
hPGH is the product of the GH2 gene and is structurally distinct from pituitary GH, from 
which it differs by 13 amino acids and an N-glycosylation site (Alsat et al., 1998, Lacroix et 
al., 2002). From 12–20 weeks to term hPGH in the maternal circulation gradually substitutes 
for pituitary GH which becomes undetectable after 20-24 weeks of gestation. hPGH is 
secreted by the placenta in a non-pulsatile manner and not regulated by GHRH (Lacroix et al., 
2002, Freemark, 2006). It is a major determinant of maternal insulin resistance in pregnancy. 
The continuous secretion of hPGH appears to have important implications for physiological 
adjustment to gestation and especially in the control of maternal IGF1 levels. PGH secretion 
is regulated in vitro and in vivo by glucose. 
 
Reduced maternal levels of PGH are observed in pregnancies with fetal growth retardation 
(Lacroix et al., 2002). It has been suggested that hPGH has an autocrine/paracrine role in the 
regulation of trophoblast invasion and interestingly, it is more efficient than pituitary GH in 
stimulating extravillous cytotrophoblast invasiveness (Lacroix et al., 2005). 
 
1.3.2.3. Adipocytokines 
Adipose tissue secretes a number of hormones, called adipocytokines, which are important in 
modulating maternal and fetal metabolism. Adipocytokines are produced by the placenta and 
include different hormones such as leptin, adiponectin, ghrelin, tumor necrosis factor (TNF), 
interleukin 6, visfatin, resistin, and apelin (Briana and Malamitsi-Puchner, 2009). 
 
Adiponectin is an adipose tissue–derived plasma protein that is involved in regulation of 
insulin resistance and glucose homeostasis and consequently is a plausible candidate for 
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regulation of intrauterine fetal development. Furthermore, conditions associated with 
increased insulin resistance, such as gestational diabetes and preeclampsia, may be influenced 
by this hormone (Mazaki-Tovi et al., 2005b). Serum adiponectin concentration was reported 
to be significantly lower in the growth restricted fetuses compared with macrosomic and 
appropriate fetuses. The lower serum adiponectin concentrations and the positive correlation 
with birth weight in the FGR, suggest that this hormone may participate in the regulation of 
fetal growth and may be a biological marker for this process (Tovi et al., 2004). 
 
1.3.2.4. Insulin-like growth factors (IGF) 
IGF system plays a critical role in fetal and placental growth throughout gestation. In 
mammals, the IGF system consists of two ligands (IGF1 and IGF2), two receptors (IGF1R 
and IGF2R) and six binding proteins (IGFBPs). The IGF1 receptor has a high degree of 
homology with the insulin receptor and is the only IGF receptor to definitively have IGF-
mediated signalling functions. The IGF2R is identical to the cation independent mannose 6-
phosphate receptor, which functions in the trafficking of lysosomal enzymes (Jones and 
Clemmons, 1995). IGF2 is the primary growth factor and nutrient transfer supporting 
embryonic growth while IGF1, which is particularly sensitive to poor nutrition, plays an 
important role in late gestation to ensure normal fetal growth and appropriate birth weight at 
delivery. Disruption of the IGF1, IGF2 or IGF1R gene retards fetal growth, whereas 
disruption of IGF2R or overexpression of IGF2 enhances fetal growth (Gicquel and Le Bouc, 
2006). 
 
Imprinting plays a key role in the IGF system. For instance, the IGF2 gene is paternally 
expressed so in heterozygous carriers following disruption of the paternal gene the growth 
retardation phenotype is expressed, whereas the IGF2R gene is maternally expressed. Some 
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growth disorders such as Beckwith-Wiedemann syndrome and Silver-Russell syndrome are 
linked with disruption of this imprinting (Gicquel and Le Bouc, 2006). 
 
1.3.2.5. Human chorionic gonadotropin (hCG) 
hCG is a glycoprotein composed of alpha and beta subunits. The alpha subunit is shared with 
luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating 
hormone (TSH), while the beta subunit is unique. After implantation, the syncytiotrophoblast 
produces hCG which enters the maternal blood and maintains the activity of the progesterone-
producing corpus luteum in the ovary during the first seven weeks of pregnancy (Vause and 
Saroya, 2005). Additionally, hCG stimulate production of testosterone by fetal leydig cells 
during the first and second trimesters of gestation to affect male sexual development before 
fetal LH production occurs (Huhtaniemi et al., 1977). hCG may play a role in the maintenance 
of the later stages of pregnancy by uterine vessels vasodilation and myometrium smooth 
muscle relaxation (Kurtzman et al., 2001). Similar to TSH, hCG stimulates thyroxine 
production within the thyroid (Reis et al., 2001). hCG secretion declines after 11 weeks’ 
gestation but oestrogen and progesterone secretion increase until parturition (Vause and 
Saroya, 2005). 
 
1.3.2.6. Placental hormones and prenatal diagnosis 
Some placental hormones have been described as useful biochemical markers for prenatal 
screening in the first and second trimesters. The most commonly used maternal serum 
analytes for first trimester screening include hCG and pregnancy-associated plasma protein A 
(PAPP-A), which are usually used in combination with the fetal nuchal translucency 
measurement. Second trimester screening include the measurement of blood level of alpha 
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fetoprotein (αFP), free βhCG, unconjugated estriol, and in some laboratory, inhibin A 
(Gagnon et al., 2008, Ndumbe et al., 2008). 
 
PAPP-A is a glycoprotein produced in the placenta. It is present in the maternal circulation in 
increasing concentrations during pregnancy. Low maternal serum levels are associated with 
trisomy 21, 18, and 13 and adverse pregnancy outcomes such as preterm delivery, FGR, 
preeclampsia, and stillbirth (Kirkegaard et al., 2010). 
 
In pregnancies complicated by fetal trisomy 13 and 18, first trimester maternal serum levels 
of free βhCG are decreased while it is elevated in trisomy 21. In those complicated by fetal 
sex chromosome abnormalities, free βhCG is normal (Gagnon et al., 2008). 
 
1.3.3. Immunologic role 
During pregnancy, intimate positioning of maternal and fetal cells and molecules which are 
genetically different would be expected to produce an immune rejection response by the 
maternal immune system. In immunological terms, the placenta is a semi-allograft or, as in 
some cases of surrogate pregnancies, a complete allograft. Several strategies are used by the 
trophoblast to protect the fetus from maternal immune system rejection (Bowen et al., 2002). 
 
The trophoblast cells are negative for classical major histocompatibility complex (MHC) class 
I or class II molecules that are the main targets of killer cytotoxic lymphocytes and therefore a 
T cell-mediated response is unlikely. Instead, they express a non-classical class MHC protein, 
human leukocyte antigen (HLA)-G, which is postulated to suppress maternal immune cells 
(Lefebvre et al., 2000). Moreover, the syncytiotrophoblast contains inhibitors of complement 
(Kelly et al., 1995). In addition, trophoblast cells evade the maternal immune system by 
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secretion of Fas ligand which induces immune cell apoptosis and trigger the death of Fas 
positive maternal T cells (Abrahams et al., 2004). 
 
Experiments in transgenic mice have suggested that dysfunction of both the innate (natural 
killer cells) and adaptive (T-cells and T regulatory cells) immune systems result in higher 
rates of fetal loss (Christiansen, 2013). 
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Chapter 2  
Placenta, fetal growth, and molecular mechanisms 
2.1. Fetal growth restriction (FGR) 
FGR also known as intrauterine growth restriction American College of Obestetricians and 
Gynecologists (2013) remains one of the main challenges in maternity care. A wide range of 
definitions of FGR can be found in the literature. FGR is usually defined as a failure of the 
fetus to reach its genetically predetermined growth potential. However, in practice, FGR is 
suspected if sonographic estimates of size, symmetry or fetal weight are abnormal (Miller et 
al., 2008). A diagnosis cannot usually be made by observation at a single point in time and 
requires serial measurements, but this may be of limited value from a clinical perspective. 
Current mechanisms of fetal surveillance are focused on recognition of early onset FGR and 
late onset FGR resulting in stillbirth towards the end of pregnancy remains a significant 
problem. 
 
The use of the terms ‘small for gestational age’ (SGA) and ‘FGR’ can be confusing, and the 
terms often are used interchangeably. The World Health Organization (WHO) defines FGR 
when the fetus is <10
th
 percentile, whereas the American College of Obstetricians and 
Gynecologists (ACOG) defines FGR when the fetus is <10
th
 percentile on the curve of weight 
for gestational age, and is frequently associated with placental insufficiency (Nardozza et al., 
2012). According to the recent ACOG bulletin (American College of Obestetricians and 
Gynecologists, 2013), SGA exclusively refers to the ‘newborns’ whose birth weight is less 
than the tenth percentile for gestational age. Nonetheless, the 10
th
 birth weight percentile for a 
given gestational age is the most commonly used cut-off for the definition of FGR (De Jong et 
al., 2000). Fetuses below 10
th
 birth weight percentile might be constitutionally small without 
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any pathologic condition. Customised standards for fetal growth and birth weight have 
improved the detection of FGR by better distinction between physiological and pathological 
smallness and have led to internationally applicable norms (Ego et al., 2006, Figueras and 
Gardosi, 2011). In a customised or individualised birth weight standard, birth weight is 
adjusted for physiologic factors such as birth order (parity), fetal gender, maternal height, 
weight and ethnic origin. Pathologic factors such as smoking, alcohol, chronic hypertension, 
and diabetes mellitus are not considered for this adjustment. 
 
Pathological FGR can often be distinguished from constitutional smallness by assessment of 
number of factors including prior history, serum biochemical markers such as low PAPP-A, 
raised inhibin, elevated αFP and sonographic examination, monitoring fetal weight, 
disproportionate asymmetric growth (increased head to abdominal circumference ratio), 
reductions in amniotic fluid volume and abnormal Doppler waveforms in the umbilical artery, 
ductus venosus and middle cerebral artery. 
 
2.1.1. Aetiology of FGR 
Fetal growth is the result of a complex cascade of processes which require coordination of 
components within the maternal, placental and fetal compartments. Fetal growth and 
development, and placental structure and function, are the result of the dynamic integration of 
cell proliferation, differentiation and migration. There are numerous perturbations that 
modulate these processes including hormones, growth factors, extracellular matrix proteins, 
cell surface receptors, post-receptor signalling pathways, cell cycle control proteins, and 
apoptosis. 
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The most common cause of FGR (80–90% of all cases) is a compromised supply of nutrients 
and oxygen to the fetus, which results in the disproportionate growth of the brain in relation to 
other fetal organs like liver, kidneys, pancreas, skeletal muscles, and fatty tissues (Bauer et 
al., 2003). 
 
2.1.1.1. Fetal factors 
1. Chromosomal alterations: primarily trisomy of chromosomes 13, 18 and 21 (Lin and 
Santolaya-Forgas, 1998). 
 
2. Inborn error of metabolism and genetic syndromes: gene mutations, such as the mutations 
determine the production or activity of insulin-like growth factor (Abuzzahab et al., 2003). 
 
3. Intrauterine infections: viral infections causing placentitis, lesions of the vascular 
endothelium, and fetal viraemia, with direct inhibition of cellular multiplication, obliterating 
angiopathy, and cytolysis (Neerhof, 1995). 
 
4. Multiple gestations: an important cause of FGR; about 15–30% of these pregnancies may 
have growth restriction, and it is more common in monochorionic gestations. Until 28–30 
weeks’ gestation, the fetus in a multiple gestation has growth very similar to that of a single 
gestation, but from this time on, there is a 15–20% decrease in growth velocity (Blickstein, 
2004). 
 
2.1.1.2. Maternal factors 
1. Clinical conditions: hypertensive disorders of pregnancy increase the incidence of FGR due 
to decreased uterine–placental perfusion. There is a strong association between preeclampsia 
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and FGR due to deficient trophoblastic invasion (Lyall et al., 2001). Other diseases, such as 
insulin-dependent diabetes mellitus with vasculopathy, severe renal conditions, autoimmune 
diseases (collagenoses, antiphospholipid antibody syndrome), hereditary or acquired 
thrombophilia, hyperhomocysteinemia, and severe anaemia are also associated with FGR 
(Howley et al., 2005, Carolis et al., 2012). 
 
2. Nutritional disorders: Maternal nutrition plays a crucial role in influencing fetal growth and 
birth outcomes (Abu-Saad and Fraser, 2010). There is growing evidence that maternal 
nutritional status can alter the epigenetic state (stable alterations of gene expression through 
DNA methylation and histone modifications) of the fetal genome. This may provide a 
molecular mechanism for the impact of maternal nutrition on both fetal programming and 
genomic imprinting. Promoting optimal nutrition will not only ensure optimal fetal 
development, but will also reduce the risk of chronic diseases in adults (Wu et al., 2004). 
 
3. The use of drugs: Alcohol and drug use by pregnant women are harmful to the developing 
embryo and fetus, and in the majority of cases also cause FGR. Exposure to carbon monoxide 
reduces the capacity of fetal haemoglobin to carry oxygen. Cigarette smoking reduces plasma 
leptin concentration in vivo, whereas nicotine has been shown to have no direct effect on 
leptin expression in vitro. Nicotine possibly reduces leptin secretion indirectly via enhanced 
plasma catecholamine concentration (Salmasi et al., 2010) by increasing the maternal 
catecholamines, nicotine also reduces placental perfusion. Equally, passive smoking, use of 
drugs (such as cocaine, heroin and others), alcohol, the inadvertent use of teratogenic 
substances (anticonvulsants, warfarin anticoagulants, antineoplastic agents, and folic acid 
antagonists), exposure to radiation, and living at high altitudes comprise aetiologic factors of 
FGR (Streissguth et al., 1981). 
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4. Other factors: Constitutional factors such as fetal gender, parity, maternal age, and maternal 
height can affect the birth weight. Observations have shown birth weight distribution was 
shifted to lower birth weight in ethnic minority groups; however, it is debateable whether 
such differences are merely due to ethnicity or other factors such constitutional and 
environmental (smoking, drinking, depression, stress, etc.) factors play a role in this condition 
(Goedhart et al., 2008). 
 
Table 2.1   Maternal, fetal, and placental causes of FGR 
Maternal Fetal Placental 
•Reduction in uteroplacental blood 
flow 
•Diminished caloric intake 
•Uterine malformations 
•Previous pregnancy with FGR 
•Low pre-pregnancy weight 
•Low socioeconomic status 
•Smoking, alcohol, illicit drugs 
•Maternal age: <16 yrs, >35 yrs 
•Assisted reproductive technology 
•Teratogens: anticonvulsants, 
methotrexate, warfarin 
•Vascular disease: chronic 
hypertension, pre-gestational 
diabetes, antiphospholipid antibody 
syndrome, collagen vascular disease 
(e.g., systemic lupus erythematosus, 
thrombophilia, renal disease, 
Crohn’s disease, ulcerative colitis) 
•Hypoxemia, high altitude  
•Anaemia including 
haemoglobinopathies 
•Genetic factors 
•Congenital anomalies 
•Multiple gestation 
•Infections: cytomegalovirus, 
syphilis, rubella, varicella, 
toxoplasmosis, tuberculosis, HIV, 
congenital malaria 
•Aneuploidies: trisomy 13, 18, 21 
•Chromosomal microdeletions 
•Imprinting: Russell-Silver 
syndrome 
•Uteroplacental vascular 
insufficiency 
•Chorionic separation (partial 
abruption, haematoma) 
•Extensive villous infarction 
•Marginal or velamentous cord 
insertion (chorion regression) 
•Confined placental mosaicism 
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2.1.1.3. Placental factors 
The most common pathological finding at delivery in severe FGR pregnancies and in third 
trimester ‘unexplained’ stillbirths is gross and histopathologic evidence of uteroplacental 
vascular insufficiency which is morphologically characterised by placental infarction (Laurini 
et al., 1994, Lausman et al., 2012). Progressive uteroplacental dysfunction leads to placental 
respiratory failure and is associated with an increased incidence of perinatal asphyxia and 
neurodevelopmental disorders (Burke et al., 2006). 
 
2.1.2. Placental adaptation to the maternal environment 
The placenta is not just a passive participant in pregnancy supplying maternal substrates to the 
fetus. It also has a capacity to supply nutrients in response to intrinsic and extrinsic variations 
in the maternal-fetal environment in order to maximise fetal growth and viability at birth. The 
various homeostatic mechanisms within the placenta and their interaction with maternal 
physiological adaptations during pregnancy act to ensure a constant supply of substrate to the 
fetus, free of large diurnal fluctuations corresponding to the timing of maternal meals, and to 
protect the fetus against a transiently poor intake during critical periods of fetal growth 
(Haggarty, 2005). These adaptations help the mother to meet the full fetal requirement for 
nutrients; however, some of these adaptations may also affect the development of individual 
fetal tissues, with pathophysiological consequences long after birth (Sandovici et al., 2012). If 
these responses are truly adaptive, then they should be detectable within the physiological 
range. Indeed, in more pathological situations the adaptations may be compromised by severe 
stress responses aimed at ensuring placental cell survival and conserving energy levels by all 
the maternal and feto-placental tissues (Burton and Fowden, 2012). 
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Adaptation in placental supply capacity might occur in three components: blood flow, 
exchange barrier surface area and transporter activity and expression. Changes in blood flow 
will predominantly affect transfer of small hydrophobic solutes such as the respiratory gases. 
Changes in exchange surface area will have predominant effects on hydrophilic solutes such 
as glucose and amino acids while transporter activity adaptations will have highly specific 
effects on transfer of particular solutes (Sibley et al., 2010). For instance, the activity of 
placental transporters for cationic and neutral amino acids is reduced in FGR; whereas, 
Placental System A activity can be up-regulated in small normal babies to meet the demands 
of fetal growth, its reduced activity in FGR result in impaired leucine transport to the fetus 
(Jansson et al., 1998). However, activity of the Ca
2+
-ATPase goes up (Strid et al., 2003) and 
some other transporters, such as the GLUT1 do not change at all (Jansson et al., 1993). 
Interestingly, the activity of some placental transporters such as System A increases over the 
course of gestation, whilst that of others like Na
+
/H
+
 exchanger decreases. These variations in 
placental transporters suggest adaptive responses to different fetal demands on the placenta as 
it develops and grows (Mahendran et al., 1994). 
 
Abnormal stimuli that alter placental development include hypoxia, oxidative and nitrative 
stress, and abnormal maternal nutrient status. These changes lead to alterations in placental 
transporter expression and activity or to epigenetic regulation of placental gene expression to 
maintain fetal growth. In addition, these stresses may be a general underlying mechanism that 
links altered placental function to fetal programming. Hypoxia is physiological for 
organogenesis and placental tissue normally exists in a relatively hypoxic environment, but 
FGR and preeclampsia are associated with a greater degree of trophoblast hypoxia (Myatt, 
2006). Cultured term human trophoblasts have shown reduced expression and activity of 
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System A amino acid transporter and increased expression of GLUT in hypoxic condition 
(Esterman et al., 1997, Nelson et al., 2003). 
 
Observations in the human placenta at high altitude have shown that changes in placental 
metabolism occur due to a reduction in mitochondrial activity to conserve the supply of 
oxygen to the fetus; but at the cost of less glucose availability because of increased anaerobic 
glucose consumption which result in hypoglycemia-mediated decrease in fetal growth (Illsley 
et al., 2010). 
 
Short term maternal food deprivation in the mouse has been linked to changes in gene 
expression related to autophagy and ribosomal turnover in the placenta in order to maintain 
the flow of nutrients to the developing hypothalamus. The fetus controls its own destiny in 
times of acute starvation by short-term sacrifice of the placenta to preserve brain development 
(Broad and Keverne, 2011). 
 
Further support for the concept of adaptation in placental supply capacity to meet fetal 
demand comes from analysis of the relationship between placental and fetal weight. Analysis 
of placental weight, birth weight and their ratio in 1,569 FGR and 15,047 normal infants 
showed that growth restricted infants had smaller placentae than normal infants when 
gestational age was used as a covariate, suggesting that fetal growth depends on the actual 
weight of the placenta and also that the placental transfer efficiency seems to be actually 
greater in growth restricted infants (Heinonen et al., 2001). Others report that the ratio of 
placental weight to birth weight is not an accurate marker of fetal growth (Williams et al., 
1997). This reflects the role of multiple and complex determinants of placental supply 
capacity in order to meet fetal demand. 
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2.1.3. Placenta and pathogenesis of FGR 
As the placenta is the regulator of nutrient composition and supply from mother to fetus and 
the source of hormonal signals that affect maternal and fetal metabolism, appropriate 
development of the placenta is crucial for normal fetal development. Placental function 
evolves in a carefully orchestrated developmental cascade throughout gestation. Interactions 
between maternal and fetal placental circulations are fundamental for an adequate exchange 
of oxygen and nutrients Abnormal development of the trophoblast or placental vasculature 
and disruption of this cascade may lead to abnormal fetal development (Myatt, 2006). 
 
As discussed in section 2.1.1 the aetiologies of FGR are diverse which make understanding of 
the pathophysiology difficult. Defects in all the trophoblast-differentiating pathways 
(endovascular, interstitial and chorionic villous) play a role in the pathogenesis of early onset 
FGR. Since uteroplacental insufficiency is a common cause of FGR and may be amenable to 
therapy in the future, particular focus is placed on the mechanisms involved in the placenta 
(Sankaran and Kyle, 2009). 
 
Between the sixth and twelfth weeks of pregnancy, cytotrophoblast invasion is established in 
the decidual tissues, including within intradecidual segments of the spiral arteries. A second 
wave of trophoblast invasion occurs between 16 and 18 weeks, when endovascular invasion is 
extended to the intramyometrial portion of the spiral arteries. These vessels lose their muscle 
and elastic layers (replaced by a fibrin matrix), resulting in a significant drop in resistance to 
flow and less responsiveness to local vasoconstrictive agents (Nardozza et al., 2012). 
Incomplete trophoblast migration will result in failure in the destruction of the muscle and 
elastic portion of the spiral arteries and this in turn will result in maintenance of a high 
resistance rather than a low resistance circulation. A failure in trophoblast invasion is also 
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associated with passage of nutritients across the intervillous space, and the possibility of 
greater vasoconstrictive action, since innervation is not affected (Nardozza et al., 2012). 
 
  
 
     28 
2.1.3.1. Placental blood flow 
Both maternal and fetal blood flows and their distribution will influence placental exchange. 
Doppler velocimetry analysis has shown reduced blood flow in both the uterine and umbilical 
arteries in FGR, that is the reduced blood flow on both sides of the placental exchange barrier. 
For exchange to be optimal, placental blood flows should match the permeability of the 
barrier. If permeability is low, then the amount of substance transferred across the barrier will 
depend largely on the permeability characteristics of the membrane and will be little 
influenced by blood flows. Such substances are said to be diffusion limited and many 
hydrophilic substances belong to this group. If, on the other hand, one or both blood flows are 
low and permeability is high, net flux depends on flow and is little influenced by the 
permeability characteristics of the membrane. Therefore, the transfer of a molecule across a 
barrier may be limited by the actual diffusion (diffusion-limitation) or by the rate of blood 
flow (blood flow-limitation). Examples of molecules subjected to blood flow-limited 
transport are carbon dioxide, oxygen and antipyrine (Schröder, 1995). Thus, it is likely that 
the reduction in placental blood flows contribute to fetal hypoxia in FGR. Indeed, in utero 
cord blood sampling has demonstrated that FGR is associated with hypoxemia. In contrast, 
transplacental transport of nutrients such as glucose and amino acids will be less affected by 
changes in blood flow since the transport across the barrier is the primary limiting factor for 
the transfer of these molecules (Jansson and Powell, 2006). 
 
In FGR, uterine venous samples show significantly higher oxygen content (larger 
transplacental gradients) and lower coefficients of uterine oxygen extraction which means that 
in FGR pregnancies the placenta simulates a relatively inefficient venous equilibrator, and 
both perfusion pattern and placental structure might be affected (Pardi et al., 1992). This 
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suggests that the impairment of the fetoplacental circulation in the villi is of considerably 
greater importance etiologically than changes in uterine blood flow. 
 
2.1.3.2. Placental nutrient transport in FGR  
The two polarised plasma membranes of the syncytiotrophoblast represent the primary barrier 
for transplacental transfer of nutrients and most ions. The plasma membrane directed towards 
the maternal compartment is the MVM whereas the basal plasma membrane (BM) faces the 
fetal capillaries. It has been hypothesized that FGR is associated with alterations in the 
activity of placental transporters which may contribute to the growth restriction. 
 
Transport of amino acids across the human placenta is an active process resulting in amino 
acid concentrations in the fetal circulation that are substantially higher than those in maternal 
plasma. The System A transporter (expressed by genes SLC38-A1, -A2 and, -A4), which is a 
Na
+
-dependent transporter, is critical in mediating the uptake of non-essential neutral amino 
acids (glycine, serine, alanine) across the MVM (Jansson, 2001). In normal pregnancies, 
smaller babies with a lower abdominal circumference but within normal range of birth weight 
have higher MVM System A activity (Godfrey et al., 1998). By contrast, MVM System A 
activity is markedly reduced in FGR especially in those babies who are delivered prematurely 
(Mahendran et al., 1993, Glazier et al., 1997, Jansson et al., 2002). Furthermore, system A 
activity is related to the severity of FGR and the most severe cases of FGR is associated with 
the most pronounced decreases in MVM System A activity (Glazier et al., 1997). In addition, 
the activity of a number of placental transport systems for essential amino acids, such as 
lysine, leucine (Jansson et al., 1998) and taurine (Norberg et al., 1998) is reduced in MVM 
and BM isolated from FGR placentas. These in vitro findings are compatible with an in vivo 
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study in pregnant women, using stable isotopes, that placental transfer of the essential amino 
acids leucine and phenylalanine is reduced in FGR (Paolini et al., 2001). 
 
The down-regulation of placental amino acid transporters in FGR results in a decreased 
delivery of amino acids to the fetus and is likely to be an important factor causing the low 
fetal plasma concentrations of certain amino acids in this pregnancy complication. Amino 
acids, together with glucose, are the primary stimulus for secretion of the most important 
growth promoting hormone, insulin, which may affect placental nutrient transfer by 
increasing the activity of the System A transporter (Jansson et al., 2003). It appears that the 
combination of decreased fetoplacental amino acid uptake and disrupted insulin/IGF 
signalling in liver and muscle account for decreased fetal growth in FGR (Regnault et al., 
2005). 
 
Transport of other solutes is also affected. FGR fetuses typically have decreased subcutaneous 
fat depots, contributing to the thin appearance of these infants. This may be due to decreased 
fetal fat synthesis or reduced placental transfer of free fatty acids. The activity of MVM 
lipoprotein lipase is critical in releasing free fatty acids incorporated in lipoproteins 
circulating in maternal blood. Indeed, reduced activity of MVM lipoprotein lipase and 
increased expression of L-fatty acid binding proteins may contribute to the altered lipid 
deposition and metabolism in FGR and diabetic pregnancies (Magnusson et al., 2004). 
Comparison of growth restricted and normal fetuses has shown differences in relative 
maternal and fetal concentrations of fatty acids such as linoleic acid and docosahexaenoic 
acid. It has been suggested that these differences may either be due to inadequate 
transplacental supply or alternatively due to the fact that the fetus lacks the enzymes 
necessary for fatty acid metabolism. These changes would then affect the feto-placental 
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biochemical environment, potentially leading to the neural and vascular complications 
associated with FGR (Cetin et al., 2002). It is important to note that some transporters do not 
show altered activity in FGR. For example, both the expression and activity of the GLUT1 in 
MVM and BM remain unchanged in FGR (Jansson et al., 1993, Jansson et al., 2002). 
 
2.1.3.3. Placental ion transport in FGR 
Placental ion transport is either correlated with fetal growth or appears to be regulated in a 
compensatory manner relative to fetal growth. Placental expression and activity of Na
+
/H
+
 
ATPase are reduced in the syncytiotrophoblast in FGR (Hughes et al., 2000). This alteration 
might be responsible for in utero acidosis in a subgroup of FGR fetuses (Nicolaides et al., 
1989). Furthermore, Na
+
/K
+ 
ATPase activity is reduced in the MVM of placentas from FGR 
pregnancies. These changes might impair the function of Na
+
-coupled transporters for vital 
nutrients such as amino acids and contribute to the reduced growth of these fetuses 
(Johansson et al., 2003). Interestingly, placental Ca
2+
 pump is activated which may be 
secondary to increased fetal Ca
2+
 demand. Mid-molecular fragment of parathyroid hormone 
related peptide (PTHrP mid-molecule) could be one of the mechanisms involved in the 
activation of BM Ca
2+ 
ATPase in FGR (Strid et al., 2003). 
 
In summary, alteration to human placental transporters in FGR is classified into three groups: 
1) those transporters that are unaffected by FGR such as glucose; 2) transporters with 
decreased activity such as System A, Na
+
/H
+
 ATPase, and Na
+
/K
+
 ATPase; 3) transporters 
with increased activity such as Ca
2+
. 
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2.1.3.4. Placental transport function in fetal overgrowth 
Fetal overgrowth represents a risk factor for operative delivery, traumatic birth injury and 
developing diabetes and obesity later in life. Since transplacental transport of glucose is a 
facilitated process, its net transfer is dependent on the concentration gradient between 
maternal and fetal blood. Pedersen’s hypothesis states that maternal hyperglycemia increases 
net transfer of glucose to the fetus and consequently increased substrate availability contribute 
to elevated fetal insulin secretion and fetal overgrowth (Pedersen, 1954). However, incidence 
of macrosomic babies remains surprisingly high despite the rigorous glycemic control of the 
pregnant woman with diabetes. In fact, this poor correlation between maternal glucose level 
and the size of baby suggests the role of other factors in fetal growth, possibly changes in 
placental transport function because of maternal diabetes. Indeed, placental activity of glucose 
transport and lipoprotein lipase have been reported to be increased in insulin-dependent 
diabetes mellitus (IDDM) associated with accelerated fetal growth, but not in gestational 
diabetes mellitus (GDM) (Jansson et al., 1999, Jansson et al., 2001, Magnusson et al., 2004). 
Thus, up-regulation of placental GLUT in IDDM may contribute to increased placental 
glucose transfer and stimulate fetal growth even if the mother is normoglycemic. 
 
Concerning amino acid transfer, diabetes in pregnancy is associated with an increased system 
A activity in MVM regardless of fetal size. It has been also reported that in pregnant women 
with GDM who have macrosomic fetus, leucine transport is increased. These changes result 
in an increased uptake of neutral amino acids across MVM, which may be used in placental 
metabolism or be delivered to the fetus (Thomas et al., 2002). Although sometimes there are 
completely different results, (Kuruvilla et al., 1994) findings in general suggest the enhanced 
placental capacity for nutrient transfer in pregnancies with diabetes. 
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2.1.4. Consequences of FGR 
FGR which accounts for almost 10% of all pregnancies is associated with distinct short- and 
long-term morbidities (Diplas et al., 2009). It is a major contributor to perinatal morbidity and 
mortality, being responsible for 50% of perinatal deaths occurring <37 weeks’ gestation and 
20% of perinatal deaths >37 weeks (Figueras et al., 2007). Immediate morbidities include 
those associated with prematurity and inadequate nutrient reserve, while childhood 
morbidities relate to impaired maturation and disrupted organ development (Christou and 
Brodsky, 2004). Long-term sequelae include metabolic and cardiovascular complications in 
later life. 
 
2.1.4.1. Short term consequences 
FGR has serious consequences for babies. It is associated with increased risk of premature 
birth and increased morbidity related to prematurity. A large meta-analysis ⁄ meta-regression 
demonstrated that FGR is associated with low Apgar scores at 5 min, sepsis, intracranial 
haemorrhage, intrauterine and neonatal death, necrotising enterocolitis (NEC) and respiratory 
complications such as respiratory distress compared with a normally grown cohort (Edwards 
and Ferguson-Smith, 2007, Damodaram et al., 2011). Although antenatal steroids have a 
beneficial effect on reducing some of these morbidities, the adrenal gland in FGR fetuses is 
already stimulated due to intrauterine stress these patients may not respond to exogenous 
steroid administration (Longo et al., 2012). However, exposure to glucocorticoids either 
antenatally to accelerate lung maturation or postnatally to facilitate weaning from mechanical 
ventilation may result in later adverse renal or cardiovascular outcomes (Bensky et al., 1996, 
Wintour et al., 2003). 
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Abnormalities of the fetal mesenteric circulation as a part of changes associated with 
circulatory redistribution, combined with fetal hypoxia, could result in hypoxic-ischaemic 
injury of the bowel and development of NEC. Retinopathy of prematurity also seems to occur 
due to intrauterine hypoxia, altered levels of growth factors and diminished antioxidant 
capacity (Longo et al., 2012). 
 
Babies with growth restriction develop ‘fetal distress’ and metabolic acidosis more frequently, 
and are more likely to develop hypoxic encephalopathy and cerebral palsy (Jarvis et al., 2003, 
M. Kady and Gardosi, 2004). 
  
Neonatal polycythaemia and thrombocytopenia are more evident in growth restricted 
newborns. Chronic intrauterine hypoxia is assumed to be responsible for the increase of 
erythropoietin and impairment of thrombopoiesis in these newborns (Wasiluk et al., 2009). 
 
FGR infants are at an increased risk for thermoregulatory disturbances. Ideally, these infants 
can increase heat production to compensate for excessive heat loss because brown adipose 
tissue stores are not usually depleted. If heat loss, exacerbated by a relatively large body 
surface area and decreased subcutaneous tissue, is allowed to continue, hypothermia will 
ensue. Both hypoxia and hypoglycaemia can interfere with heat production and may be 
pathogenically implicated in the disrupted thermoregulatory response after FGR (Rosenberg, 
2008). 
 
Fasting hypoglycemia is another issue of major concern for the FGR infant. The 
hypoglycemia in the FGR infant is due primarily to decreased glycogen stores (the 
predominant source of glucose in the first hours after birth) with a possible contribution from 
 
     35 
diminished glucose production in the liver from alanine and lactate via gluconeogenesis 
(Rosenberg, 2008). In early postnatal life, FGR infants display increased insulin sensitivity 
with respect to glucose disposal but not with respect to suppression of lipolysis, ketogenesis, 
and hepatic production of IGF-binding protein-1 (IGFBP-1) (Bazaes et al., 2003). 
 
2.1.4.2. Long term consequences 
Intrauterine programming is defined as a permanent or long-term change to the physiology, 
morphology or metabolism of a fetus or neonate in response to a specific insult or stimulus at 
a critical period in development (Barker, 2001). A reduction in nutrients below that required 
for optimal fetal growth ‘reprograms’ the offspring via permanent structural and functional 
changes that, in the context of postnatal nutrient surfeit, predispose to disease syndrome 
(Chernausek, 2012). Changes in the concentrations of metabolites such as amino acids, 
glucose, and Ca
2+
 in body fluid compartments will alter homeostatic set points with life-long 
effects on how the individual reacts to changes in his or her environment (Sibley et al., 2010). 
 
The ‘fetal origins of adult disease’ hypothesis proposes that type 2 diabetes mellitus, obesity, 
hypertension, dyslipidemia, and insulin resistance (the metabolic syndrome), as well as 
coronary heart disease and stroke originate in developmental plasticity, in response to under-
nutrition during fetal life and infancy (Barker, 2004). Animal models suggest that leptin 
deficiency or, alternatively, leptin resistance may contribute to the pathogenesis of the 
metabolic syndrome in the FGR. Leptin is a 16-kilodalton hormone synthesized by and 
secreted from the adipose tissue. It acts on the nervous system, adipose tissue, respiratory and 
immune systems, and skeletal growth control. It circulates in direct proportion to body fat 
stores, enters the brain and regulates food intake and energy expenditure. Deficient leptin 
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neuronal signalling favours weight gain by affecting the central homeostatic circuitry (Bar-El 
Dadon et al., 2011, Coupé et al., 2012). 
 
FGR may permanently alter the endocrine–metabolic status of the fetus, driving an insulin 
resistance state that can promote survival at the short term but that facilitates the development 
of type 2 diabetes mellitus in adult life (Kanaka-Gantenbein, 2010). A significant fetal 
adaptation to poor nutrition is an up-regulation of the insulin receptor without the up-
regulation of insulin signalling in fetal skeletal muscle. After birth, however, there is an up-
regulation of both the insulin receptor and the insulin signalling pathway in the FGR infant. In 
suboptimal nutritional environment, adaptive responses result in the development of a ‘thrifty 
phenotype’ in which there is a relative decrease in overall body growth and in the growth of 
organs such as the gut and liver, while there is differential sparing of the growth of key organs 
such as the brain and heart (Longo et al., 2012). Brenner and colleagues hypothesized that 
FGR may cause a low nephron number, thus predisposing to later hypertension and renal 
disease (Brenner et al., 1988). Subsequent studies showed that FGR were associated with mild 
to moderate elevations of blood pressure, reduced numbers of compensatory hypertrophied 
glomeruli, lower glomerular filtration rate and higher urine albumin-to-creatinine ratio (Chan 
et al., 2010). Moreover, there are strong pointers to the importance of maternal body 
composition and dietary balance during pregnancy that results in impaired fetal development 
and consequently programme adult cardiovascular disease (Godfrey and Barker, 2001). 
 
Fibrinolysis disorders have been proposed as one putative link between metabolic syndrome 
and cardiovascular disease. Plasminogen activator inhibitor type-1 (PAI-1) is strongly 
associated with metabolic syndrome and identified as a predictive marker for myocardial 
infarction. Meas et al., found that elevation of PAI-1 plasma concentrations are significantly 
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increased in adults born SGA independently of the presence of metabolic syndrome or 
insulin-resistance (Meas et al., 2010). 
 
Other adverse outcomes of FGR include short stature in children and adults, premature 
adrenarche, ACTH-adrenal gland axis disturbance, polycystic ovarian syndrome, neurological 
sequelae, and motor and cognitive delay (Baschat, 2011, Roth and Sathyanarayana, 2012). 
Reduced bone mineralization both in childhood and in adult age osteoporosis later in life has 
also been reported (Jansson and Powell, 2006). On the other hand, epidemiological studies 
has shown that adverse pregnancy outcomes such as preeclampsia, preterm delivery, and low 
birth weight are associated with increased risk for the affected women for cardiovascular 
disease in later life (Smith et al., 2001). Therefore, FGR is an important condition that 
requires clinical awareness and health service focus on developing better strategies for the 
early detection of FGR. 
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Chapter 3  
Aims and hypothesis 
Abnormal fetal growth is a common complication of pregnancy. Suboptimal fetal growth 
occurring in FGR fetuses is an important cause of perinatal mortality and morbidity. 
Moreover, an association has been demonstrated between low birth weight percentile and late 
onset adult diseases. We hypothesize that abnormal rates of fetal growth are a reflection of 
placental function and that this is associated with changes in placental gene expression. 
 
One of the most popular applications of microarrays is to compare expression of a set of 
genes from a sample maintained in a particular condition to the same set of genes from a 
reference sample. Genome-wide expression analysis of placental tissue may provide valuable 
insight regarding genes and pathways influencing fetal growth. 
 
This study aims to identify changes in placental gene expression in term pregnancies with 
abnormal patterns of fetal growth using GeneAtlas 3’ IVT Express Kit (Affymetrix HG-U219 
array strip) which provides wide coverage of the transcribed genome with total probes 
number of 49411 derived from UniGene, RefSeq, NCBI genome version, UCSC, Ensembl, 
GenBank, and Entrez data sources (25-mer probes interrogating 9 to 11 unique sequences of 
each transcript - interrogate up to 275 bases per transcript). 
 
Results of this study may be of future value in defining pregnancies at risk of fetal morbidity 
and mortality related to growth dysfunction. In addition, findings of this research might help 
to identify novel biomarkers for the screening, early detection, and management of FGR 
which is difficult to predict using current techniques. 
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Hypothesis 1: 
There is a difference in the placental gene expression profile and signalling between FGR and 
normal infants. 
 
Hypothesis 2: 
There is a difference in the placental gene expression profile and signalling pathways between 
macrosomic and normal infants. 
 
Hypothesis 3: 
Differentially expressed genes involved in abnormal fetal growth (either FGR or macrosomia) 
have molecular and biological functions associated with adult-onset disease. 
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Chapter 4  
Methodology 
4.1. Sample collection and processing 
This study was approved by the Human Ethics Committees of Royal Prince Alfred Hospital 
(RPAH) (protocol no. X11-0252 & HREC/11/RPAH/385) and the University of Sydney 
(project no. 2013/116). Written, informed consent was obtained from the mother of each 
newborn. 
 
Placentas and maternal blood samples were collected from 194 pregnant women being 
admitted for delivery at RPAH between 1 February 2012 to 31 August 2012. These samples 
were collected from elective Caesarean section and vaginal deliveries between 23 to 40 
weeks’ gestation. Samples were collected from normal pregnancies and those complicated by 
FGR, preeclampsia, and gestational diabetes. The placentas collected during this period 
included both male and female infants with birth weights ranging from 990gm to 5079gm 
(gestational adjusted birth weights from 1
st
 to 99
th
 percentile). The vast majority of samples 
were obtained from singleton pregnancies however samples from some twins and triplets 
were also collected. 
 
Tissue samples from Caesarean section were collected and processed immediately after 
delivery but those from vaginal delivery were initially stored at 4°C after delivery before 
being collected and processed. A 1cm × 1cm piece of tissue was removed from the central 
part of each placenta, directly behind the cord insertion site, and placed in cold normal saline. 
Placental tissue was excised from the fetal surface of the placenta after removing the maternal 
surface and visible vessels. The sample was rinsed extensively with sterile saline solution to 
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minimize maternal blood contamination. The tissue sample was then divided into sixteen 
smaller pieces (~ 100mg). Eight were transferred to 2mL tubes and immersed in 1.5mL 
volume of RNALater (Ambion, USA), an RNA stabilisation reagent. These were incubated at 
4°C for 24 hours and then transferred to -80°C. The remaining eight pieces were stored frozen 
at -80°C, in sterile normal saline. 
 
4.2. Description of samples used in the experiments 
A series of placental samples were selected from a placental tissue bank to provide 
representative examples of normal newborns, FGR and macrosomia. 
 
The control group included infants born with a birth weight centile between 40% and 60%, in 
the FGR group, infants were defined with birth weight centile <10% and the macrosomic 
group was defined as a birth weight centile >90% (Sacks, 2007). Birth weight centiles were 
calculated based on gestational age, the newborn’s sex and birth weight with a tool provided 
on the Royal Prince Alfred Hospital Neonatal Unit website (http://www.sswahs.nsw.gov.au-
/RPA/neonatal/default.htm) (Beeby et al., 1996). 
 
For consistency and to reduce the number of biological variables, we selected placental 
samples from pregnancies with male infants that were delivered at 39 weeks’ gestation by 
elective Caesarean section for the remaining work. None of the mothers smoked or had a 
history of alcohol / illicit drug use during pregnancy. 
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Table 4.1   Inclusion and exclusion criteria for the samples used in the experiment 
Exclusion criteria Inclusion Criteria 
Female babies 
Fetuses with prenatal diagnosis of chromosomal 
abnormality  
Malformation syndromes 
Normal vaginal delivery 
Preterm delivery 
Multiple pregnancy 
Mothers with chronic hypertension  
Smoking during pregnancy 
Male babies 
Term pregnancy (39 weeks) 
Caesarean section delivery 
Normal PAPP-A level
*
 
Non-smoker mothers 
 
 
 
*
PAPP-A, Pregnancy-associated plasma protein A measured in first trimester. 
 
 
4.3. RNA extraction from placenta 
Total RNA was extracted from all samples using TRIzol reagent and PureLink RNA Mini 
Kits (Life Technologies Australia Pty Ltd, VIC, Australia) according to the manufacturer’s 
specifications. In brief, one tube of each sample, containing 100-150 mg tissue was used. The 
RNALater was discarded, the tissue divided into two approximately equal parts using a sterile 
scalpel and placed into 2 x 2mL RNase-free microfuge tubes, each containing 1mL TRIzol 
reagent. Mechanical disruption of tissues was performed using 5mm stainless steel beads and 
the tissue lyser system (TissueLyser LT, Qiagen, Germany) for 5mins at 50 Hertz oscillation 
frequency. 
 
50μl 4-bromoanisole per 1mL TRIzol reagent was added and mixed vigorously for 15secs. 
Following incubation at room temperature for 3mins the lysate was centrifuged at 12,000g at 
4°C for 15mins. Approximately 400μl of the clear supernatant containing the RNA was 
transferred to a fresh 2mL RNase–free tube and an equivalent volume of 70% (v/v) ethanol 
was added and vortexed for 1min until the ethanol was completely homogenised with the 
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lysate and any precipitates were dissolved. Afterwards, the binding, washing, and elution 
steps were performed. 
 
Up to 700μl, at a time, of the new solution were transferred to a spin cartridge (PureLink 
RNA Mini Kit, Invitrogen) and centrifuged at 12,000g for 15-20 secs at room temperature and 
the filterate was discarded. These steps were repeated until the whole sample was spun 
through the spin column. Next, 700μl of wash buffer I (7-13% guanidine hydrochloride 
solution) was added to the spin cartridge - with the extracted total RNA bound to the silica 
filter and centrifuged at 12,000 g for 15-20 secs. 
 
The spin cartridge was then transferred to a new collection tube and centrifuged at 12,000g 
for 15-20 secs with 500μl of wash buffer II. This process was repeated, the wash discarded 
and the filter centrifuged at 13,000g for 2mins to dry the membrane and eliminate as many 
contaminants carried over during the purification process. 
 
For elution of total RNA, the spin cartridge was incubated in a new collection tube with 60μl 
of RNase-free water for 2mins at room temperature, centrifuged at 15,000g for 2mins and the 
flow through was immediately stored on ice and transferred to -80°C. This step was repeated 
in a new collection tube with 60μl of RNase-free water to retrieve the maximum amount of 
RNA as possible. 
 
4.4. Total RNA purity and concentration assessments 
Total RNA was assessed using NanoDrop (Thermo Fisher Scientific Australia Pty Ltd, VIC, 
Australia) to evaluate and determine the RNA concentration (ng/μl) and the presence of 
contaminants carried over in the sample (based on 260/230 and 260/280 ratios). 1.5µl of 
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RNase-free water was added to register a blank measurement as the reference parameter. 
1.5μl of each of the elutions was placed in the NanoDrop ND1000 spectrophotometer and the 
measurements were recorded and then stored for further analysis. 
 
Nucleic acids are traditionally quantified by measuring UV absorption using a 
spectrophotometer. The spectrophotometer registers the absorbance of all the molecules 
present in the sample. The concentration of nucleic acid can be determined using the Beer-
Lambert law, which predicts a linear change in absorbance with concentration. RNA has its 
absorption maximum at 260nm and the ratio of the absorbance at 260nm and 280nm is used 
to assess the RNA purity of an RNA preparation. A 260/280 ratio of ~2.0 is generally 
accepted as ‘pure’ for RNA. If the ratio is appreciably lower it may indicate either the 
presence of protein, phenol or other contaminants that absorb strongly at ~280nm or a very 
low concentration (less than 10ng/µl) of nucleic acid. High 260/280 ratios are not indicative 
of an issue. 
 
The 260/230 ratio is used as a secondary measure of nucleic acid purity. This value for ‘pure’ 
nucleic acid is often higher than the respective 260/280 value. Expected 260/230 values are 
commonly in the range of 2.0 to 2.2. If the ratio is appreciably lower than expected, it may 
indicate the presence of contaminants which absorb at 230nm such as phenol and 
ethylenediaminetetraacetic acid. The TRIzol reagent is a phenolic solution which absorbs in 
the UV both at 230nm and 270nm. Guanidine isothiocyanate, used for RNA isolations will 
absorb at 260nm [Thermo Scientific; T042 & T009 - Technical bulletin]. 
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4.5. Total RNA quality assessment 
Aliquots from each sample were analysed for RNA preservation with the 2100 Bioanalyzer 
assay (Agilent Technologies, VIC, Australia). Under aluminium foil to ensure minimal loss of 
fluorescence, the RNA 6000 Nano Gel Matrix was spun through a filter at 1,500g for 10mins 
at room temperature. 1μl of RNA Nano Dye Concentrate was then added to 65μl of filtered 
gel and the mixture was vortexed and centrifuged at 13,000g for 10mins. 
 
Prior to loading, 2μl of Agilent RNA 6000 Nano Ladder and 2μl of each sample were heated 
at 70°C for 2mins in a pre-heated PCR thermal cycler (BioRad T100 gradient thermal cycler) 
to induce nucleotide denaturation and immediately placed on ice to avoid reformation of 
bonds between nucleotide strands. 
 
The RNA Nano 6000 Labchip was loaded into the chip priming station (set in the C position) 
with the syringe loaded with 1mL of air. 9μl of gel-dye mix was added to the well. The air in 
the syringe was injected into the chip; the plunger was secured at the highest syringe clip 
position for 30secs and released, allowing 5secs for the plunger to return to its original 
position. The gel-dye mix, RNA Nano Marker, RNA Nano Ladder and 1μl of each sample 
were added to the chips. After pressurisation, the overall loading of the chip was completed 
within 5mins. 
 
Once loading was completed, the chip was vortexed using a Vortex Mixer (Model MS2-
S8/MS2-S9) at 2,400rpm for 1min, loaded onto the Bioanalyzer and examined with the 2100 
Expert software (Agilent, 2005). 
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The RNA integrity of the extracted total RNA was assessed using the Agilent RNA 6000 
nano kit of the Bioanalyzer 2100 system (Agilent Technologies, VIC, Australia). Agilent 
2100 Bioanalyzer uses a combination of microfluidics, capillary electrophoresis, and 
fluorescence to evaluate both RNA concentration and integrity. 
 
Messenger RNA (mRNA) comprises only 1-3% of total RNA samples and is therefore not 
readily detectable, even with the most sensitive of methods. Ribosomal RNA (rRNA), on the 
other hand, makes up >80% of total RNA samples. The eukaryotic ribosome (80 Svedberg 
[80S]) is consisting of a small 40S subunit and a large 60S subunit. The 60S subunit contains 
5S, 5.8S, and 28S rRNAs (120, 160, and 4800 bases, respectively) in addition to 50 proteins. 
The 40S subunit has 18S rRNAs (1900 bases) and 33 proteins (Figure 4.1). In mammalian 
systems the majority of rRNA is comprised of the 28S and 18S rRNA species. The 
Bioanalyzer system is an indirect approach to assess the mRNA integrity. Indeed, this method 
relies on the assumption that rRNA quality and quantity reflect that of the underlying mRNA 
population. 
 
Figure 4.1   Structure of eukaryotic ribosomes. 
                                                                             Proteins 
 
 
 
 
 
 
 
 
 
 
Source: http://www.mun.ca/biology/scarr/MGA2_03-23.html 
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The theoretical 28S:18S ratio is approximately 2.7:1; but a 2:1 ratio or higher has long been 
considered the benchmark for intact RNA. The Bioanalyzer 2100 system separates the RNA 
molecules using electrophoresis and registers the fluorescence trace, creating an 
electropherogram and a gel image (Figure 4.2). Using this tool, RNA Integrity Number (RIN) 
is determined by the ratio of the ribosomal bands as well as the RNA area under the sample 
peaks and also entire electrophoretic trace of the RNA sample, including the presence or 
absence of degradation products (Schroeder et al., 2006). 
 
Figure 4.2   Principle of injection and separation of RNA in Bioanalyzer 2100. 
         1                    2                    3                    4 
 
 
4.6. Microarrays 
Microarray analysis was performed using Affymetrix HG-U219 array strips (~530,000 probes 
containing 49,411 probe sets which cover more than 36,000 transcripts and variants through 
UniGene or via RefSeq annotation) following RNA sample preparation with a GeneChip 3’ 
IVT Express Kit (Manufactured for Affymerix, Inc. by Ambion Inc., USA) according to the 
manufacturer’s guidelines. All samples were diluted with RNAse free water (MiliQ) to an 
RNA concentration of approximately 250ng/µl. They all met the required A260 / A280 ratio 
(1.7 - 2.1). The steps of complementary DNA (cDNA) synthesis, in vitro transcription (IVT), 
1. The sample moves through the micro-
channels from the sample well. 
2. The sample is injected into the 
separation channel. 
3. Sample components are 
electrophoretically separated. 
4. Components are detected by their 
fluorescence. 
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fragmentation, labelling, hybridisation, fluidics, and imaging were performed as the 
manufacturer’s instruction (Figure 4.3). 
 
Figure 4.3   Overview of the GeneAtlas 3’ IVT Express Kit Labelling Assay. 
 
Source: GeneAtlas 3’ IVT Manual 
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4.6.1. Reverse transcription to synthesize first-strand cDNA 
Reagents were removed from the freezer 20mins prior to synthesizing first-strand cDNA to 
thaw at room temperature before being placed on ice. Poly-A RNA control was diluted with 
Poly-A control dilution buffer. Poly-A controls contains probe sets for several polyadenylated 
transcripts for the Bacillus subtilis genes that are absent in eukaryotic samples (lys, phe, and 
dap).They provide exogenous positive controls to monitor the target labelling process from 
start to finish. Their resultant signal intensities on arrays serve as indicators of the labelling 
reaction efficiency. The serial dilution of Poly-A RNA controls were done in non-stick 
RNase-free microfuge tubes to final concentrations of 1:100,000 (lys), 1:50,000 (phe), and 
1:6,667 (dap). 1.5µl of diluted poly-A RNA controls were added to 250ng (1µl) RNA sample. 
 
Reverse transcription in GeneAtlas 3’ IVT Express Kit involved using T7 oligo (dT) primer to 
synthesize first-strand cDNA containing a T7 promoter sequence. First-strand master mix was 
prepared in a nuclease-free tube on ice for four samples using 8.4µl first-strand buffer mix 
and 2.1µl first-strand enzyme mix. First-strand cDNA synthesis was performed with addition 
of 2.5µl first-strand master mix in individual tubes and incubation for 2 hours at 42°C in a 
thermal cycler. 
 
4.6.2. Second-strand cDNA synthesis 
To prepare second-strand master mix for four samples, 27.3µl nuclease-free water was mixed 
with 10.5µl second-strand buffer mix and 4.2µl second-strand enzyme mix on ice. After 
vortexing the assembly, 10µL of second-strand master mix was added to each (5µL) cDNA 
sample. After mixing thoroughly and brief centrifugation, the reaction was placed on a 
thermal cycler block (pre-cooled to16°C) and incubated for 1 hour at 16°C followed by 
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10mins at 65°C. Next, the tubes were centrifuged to collect 15µl double-stranded cDNA at 
the bottom of the tube and were placed on ice to proceed in vitro transcription. 
 
4.6.3. In vitro transcription to synthesize labelled aRNA 
IVT master mix was assembled by mixing 8.4µl IVT biotin label, 42µl IVT labelling buffer, 
and 12.6 µl IVT enzyme mix in a nuclease-free tube at room temperature. After vortexing and 
brief centrifugation, 15µl of IVT master mix was transferred to each (15µl) double-stranded 
cDNA sample and mixed thoroughly. In the next step, the IVT reaction was incubated for 16 
hours at 40°C in a thermal cycler. The reaction was then removed from thermal cycler and 
placed on ice, to perform aRNA purification. 
 
4.6.4. aRNA purification 
This step removes enzymes, salts, and unincorporated nucleotides. The tube containing RNA 
binding beads was flicked several times to ensure all beads had become suspended. 22µl 
‘RNA binding beads’ and 110µl ‘aRNA binding buffer concentrate’ were mixed to prepare 
‘aRNA binding mix’ for four samples. 15µl aRNA binding mix was added to each sample and 
the reaction transferred to the ‘U-bottom plate’ provided with the kit. Next, 60µl 100% 
ethanol was added to each sample, and placed on a plate shaker for 5mins at 500rpm. 
 
To capture RNA binding beads, the plate was moved onto the magnetic stand (Figure 4.4) for 
5mins. When the mixture became transparent and the RNA binding beads formed aggregate 
against the magnets in the magnetic stand, the supernatant was carefully removed and 
discarded and then the plate was removed from the magnetic stand. 
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The beads were washed 2 times. For this purpose, 80µl aRNA wash solution was added to 
each sample and the U-bottom plate was placed on a plate shaker for 1min at 900rpm. In 
order to capture the RNA binding beads, the plate was moved to a magnetic stand for 5mins. 
Then the supernatant was aspirated and discarded carefully without disturbing the RNA 
binding beads. The plate was next placed on a plate shaker for 1min at 1,200rpm to allow the 
residual ethanol to evaporate from the beads. 
 
In order to elute the purified aRNA from the RNA binding beads 30µl aRNA elution solution 
(preheated for 10mins at 60°C) was added to each sample and shaken vigorously for 3mins at 
1,200rpm. When the RNA binding beads were fully dispersed they were captured by moving 
the plate onto the magnetic stand for 5mins. The supernatant containing the eluted aRNA was 
transferred to RNAse free 0.2mL PCR tube and stored on ice ready to proceed with 
quantitation and fragmentation. 
 
4.6.5. Analysis of aRNA concentration and size 
In order to analyse the concentration of unfragmented aRNA and size distribution of 
unfragmented aRNA we used the NanoDrop and 2100 Bioanalyzer assays; as described in 
sections 4.4 and 4.5 of this chapter. All the samples met the required aRNA profile which was 
 
Figure 4.4   Magnetic stand for the 
paramagnetic bead precipitation from 
standard 96-well U-bottom plate. 
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a distribution of sizes from 250–5,500 nucleotides with most of the aRNA between 600–1,200 
nucleotides. 
 
4.6.6. Fragmentation of labelled aRNA 
A fragmentation mixture was prepared by adding 5µl of ‘5x array fragmentation buffer’ to 
10µg aRNA (the volume of aRNA was dependent on its resultant concentration as determined 
using the NanoDrop). RNAse free water was added to this mixture to achieve 25µl total 
volume and incubated at 94ºC for 35mins. The fragmented aRNA was then analysed using the 
2100 Bioanalyzer. All samples had a distribution of 35–200 nucleotides aRNA fragments 
with a peak at approximately 100-120 nucleotides. 
 
4.6.7. Hybridization 
The array strip and pre-hybridization buffer were equilibrated to room temperature. The 
barcode of the Affymetrix array strip was scanned by the GeneAtlas system and registered in 
the GeneAtlas software and sample names were accordingly assigned on the array strip. The 
temperature of the GeneAtlas hybridization station was set to 45°C. ‘Hybridization cocktail 
master mix’ was prepared according to the table 4.2. 
 
Table 4.2   Hybridization Cocktail Setup. 
Component Master Mix for 4 Arrays 
Control Oligonucleotide B2 (3nM) 11μl 
20X Hybridization Controls (bioB, bioC, bioD, cre) 33μl 
1.3X Hybridization Solution A 176μl 
1.3X Hybridization Solution B 330μl 
Nuclease-free Water 27.3μl 
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The 20X hybridization controls preheated to 65°C for 5mins. The 20X eukaryotic 
hybridization controls are comprised of a mixture of biotinylated and fragmented cRNA of 
bioB, bioC, bioD, and cre in staggered concentrations to evaluate sample hybridization 
efficiency. Control Oligo B2 is a pre-labelled DNA spike-in control required for hybridization 
to the control probes on the array utilized for grid alignment by GeneChip Software. 
 
To prepare the hybridization cocktail, 131.2µl of the hybridization cocktail master mix was 
added to 18.8µl of fragmented and labelled aRNA, thoroughly mixed and placed on ice. 120µl 
pre-hybridization buffer was pipetted into the appropriate wells of the hybridization tray and 
the array strip was placed into the tray and incubated on the hybridization station at 45°C for 
15mins. During the pre-hybridization, 120µl of the hybridization cocktail was transferred into 
a 0.2mL PCR tube and incubated at 96°C for 10mins in a thermal cycler, followed by 2mins 
at 45°C. 
 
The array strip was the removed and immersed in the pre-hybridization solution and 120µl of 
pre-heated hybridization cocktail applied to the middle of the appropriate wells of a new 
hybridization tray. The array strip was removed from the hybridization tray containing the 
pre-hybridization buffer and placed into the hybridization tray containing the hybridization 
cocktail samples. The array strip was then placed and locked in place by clamping inside the 
hybridization station. Overnight, 16 hours incubation at 45°C hybridization was performed 
using the GeneAtlas software. 
 
4.6.8. Fluidics (wash and stain) and imaging 
Following the completion of overnight hybridization, 850µl of ‘wash B’ reagent was added to 
the corresponding positions on the wash B tray and 200µl of ‘array holding buffer’ to the 
 
     54 
corresponding positions in the imaging tray. Likewise, 850µl of ‘wash A’ reagent, 350µl of 
‘stain cocktail 1’ and 350µl of ‘stain cocktail 2’ were added to the corresponding positions in 
the wash A/Strain tray (Figure 4.5). 
 
Figure 4.5   Tray maps used in the fluidics station. 
 
 
 
After loading the prepared trays to the GeneAtlas fluidics station (Figure 4.6-A) the bar code 
of the array strip was again scanned, loaded onto the appropriate deck of the fluidics station 
and the fluidics stage started. 
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Figure 4.6   The GeneAtlas fluidics station (A) and imaging station (B). 
 
 
 
When the wash and stain process was completed, after approximately 1.5 hours, the imaging 
tray and array strip were directly placed in the imaging station (after scanning the bar code of 
the array strip) and imaging of the array was performed (Figure 4.6-B). 
 
4.7. Microarrays quality control 
Once the imaging step was completed, the quality control (QC) report in the Affymetrix 
GeneAtlas operating software was assessed to ensure all samples had passed the quality 
metrics for signal, hybridization controls, labelling controls, and sample quality. Files from 
scanned chips (CEL files) were imported to the Partek Express (Affymetrix Edition) software 
using Robust Multichip Average algorithm which includes background correction, quantile 
normalisation, and median polish summarisation (Bolstad et al., 2003). 
 
A B 
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The QC metrics provides QC information from the control and experimental probes on the 
Affymetrix chips to provide confidence in the quality of the microarray data or to identify 
samples that do not pass the QC metrics. The QC metrics used for hybridization and labelling 
controls were in Log 2 intensity scale and for 3’/5’ controls in ratios. 
 
Several controls are available to monitor assay data quality, which mainly include: 
hybridization controls, labelling controls, and internal control genes. 
 
4.7.1. Signal value 
This is a measure of the average brightness of the probe set on the array, minus the 
background noise. The signal to noise ratio must be above a certain value for the array to pass 
QC. 
 
4.7.2. Hybridization controls 
Four exogenous biotin labelled molecules are spiked into the hybridization cocktail before 
hybridization, but after sample labelling. These high-quality controls (the 20X eukaryotic 
hybridization controls) which are composed of a mixture of biotinylated and fragmented 
aRNA of bioB, bioC, bioD, and cre. from E. coli in staggered concentrations are for 
monitoring array hybridization, washing, and staining for reproducible results. The 20X 
eukaryotic hybridization controls are spiked into the hybridization cocktail, independent of 
RNA sample preparation, and are thus used to evaluate sample hybridization efficiency on 
eukaryotic gene expression arrays. 
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4.7.3. Labelling controls 
Poly-A controls are added to RNA sample prior to using the IVT express kit. Three 
independent poly-A RNA controls, derived from the Lys, Phe, and Dap genes of Bacillus 
subtilis, are provided at increasing concentrations (Lys < Phe < Dap). The spikes are inserted 
into the sample prior to labelling and their resulting detection is dependent on the labelling 
reaction that labels the biological sample. After spiking directly into eukaryotic total RNA 
samples, labelled aRNA targets are prepared and hybridized onto GeneChip expression 
arrays. The resultant signal intensities for the poly-A RNA controls serve as sensitive 
indicators of the efficiency of the labelling reaction and are independent of input sample RNA 
quality. 
 
4.7.4. Sample quality (housekeeping genes) 
Housekeeping genes are gene transcripts that are constitutively expressed on most samples. 
These transcripts serve as internal controls, are useful for monitoring the quality of the 
starting sample, and are subject to any variability in the labelling of the sample and 
hybridization for the array. For 3’ expression arrays, GAPDH is used to assess RNA sample 
and assay quality. GAPDH has separate probe sets at the 3’ and 5’ end of the gene. In high-
quality samples, reverse transcriptase should process from the 3’ through towards the 5’ end. 
The 3’/5’ ratio compares the abundance of the signal at the 3’ end over the abundance at the 
5’ end. A ratio of 3 or less is considered acceptable. 
 
4.8. Gene significance estimate 
Affymetrix GeneAtlas operating software was used to first check all samples had passed all 
QC metrics. The chips were scanned and files were imported to Partek Express (Affymetrix 
Edition) software for further evaluation (Bolstad et al., 2003). Gene expression between FGR 
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or macrosomic placentas and normal controls was compared and defined statistically by 
Analysis of Variance (ANOVA) and false discovery rate. Genes with >2 fold change and p-
value <0.05 were considered to be statistically significant and differentially expressed. 
 
4.8.1. Principle component analysis (PCA) 
PCA is an excellent method for visualising high dimensional data by reducing the variation 
across all of the many thousands of probes being interrogated on the chip into a two or three 
dimensional representation. In a PCA plot, each point represents a sample (microarray) and 
their position are relative to each other. Those dots that are closer to each other represent 
samples in which the transcriptome measurements over the whole chip are similar. Those dots 
that are further away from each other represent samples in which the transcriptome 
measurements over the whole chip are more dissimilar. Samples that have similar overall 
gene expression levels will group together into clusters. 
 
4.8.2. Effect size 
Effect size provides information on the importance of each experimental factor to the 
transcriptome. Applying ANOVA, Partek Express software was used to test for the difference 
in means of a response variable between different groups. 
 
4.9. Data analysis 
In order to further investigate the gene ontology and biological function of the gene sets that 
emerged from the filtering step we utilised Ingenuity Pathways Analysis (IPA) software 
(Ingenuity System, Inc., 2013) with a biomarker filter for human placenta. IPA software was 
also used to cross check the list of differentially expressed candidate genes and to identify 
specific pathways and explore networks relevant to fetal growth and development. Fisher’s 
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exact test (p-value 0.05) was used for canonical pathway analysis. Other bioinformatics tools 
including Database for Annotation, Visualization and Integrated Discovery (DAVID), and 
Protein ANalysis THrough Evolutionary Relationships (PANTHER) (Thomas et al., 2006) 
were used to annotate gene ontology and network. Significant changes in gene and potential 
biomarker expression that were consistent in all indexes are reported. 
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Chapter 5 
Results 
5.1. Description of patients 
Total number of 15 placenta samples were analysed in this study. Compared to control group, 
the mean of maternal age was less in FGR and macrosomic groups but the p-value was not 
significant for these differences. The birth weight and birth weight centiles were significantly 
different in the three groups (p<0.001). On average, mothers of growth restricted babies 
seemed to have a less pre-pregnancy weight compared to control babies while mothers of the 
macrosomic babies had greater pre-pregnancy weight. However, these differences were not 
statistically significant (Table 5.1). 
 
 
5.2. NanoDrop results 
The concentration and purity of the total RNA extracted from the samples included in the 
microarray analyses were assessed using NanoDrop ND1000 spectrophotometer. The 
concentrations and 260/280 and 260/230 ratios of the first elutions obtained from each sample 
Table 5.1   Characteristics of patients.    
 FGR Control Macrosomia 
p-value 
(FGR) 
p-value 
(Macrosomia) 
Maternal age (years) 34.4 ± 4.6 38 ± 4.2 34.5 ± 5.0 0.23 0.25 
Gestational age (weeks) 39 39 39 - - 
Birth weight (gm) 2812.5 ± 22.4 3443.6 ± 69.7 4367.3 ± 349.9 <0.001 <0.001 
Birth weight centile <10
th
 40
th
 – 60
th
 >90
th
 <0.001 <0.001 
GDM/non-GDM ratio 0/4 2/5 1/6 - - 
Maternal weight (kg) 54.8 ± 6.1 58.5 ± 5.7 74.3 ± 19.2 0.37 0.11 
Values are shown as mean ± SD. GDM, gestational diabetes mellitus. 
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are reported in Table 5.2. All the samples included in the microarray assay had 260/280 ratios 
between 2 and 2.21 and most samples showed similar UV light absorption spectral patterns. 
 
Table 5.2   NanoDrop results. 
Sample ID 
Concentration 
(ng/µl) 
260nm 
absorbance 
280nm 
absorbance 
260/280 
Ratio 
260/230 
Ratio 
PLPP-007 835.91 20.898 9.74 2.15 2.21 
PLPP-026 761.79 19.045 8.792 2.17 2.17 
PL12-056 1315.85 32.896 15.313 2.15 2.22 
PL12-085 1404.66 35.117 16.18 2.17 2.25 
PL12-132 1330.75 33.269 15.297 2.17 2.13 
PLPP-001 1269.62 31.741 14.848 2.14 2.25 
PLPP-002 1444.2 36.105 16.73 2.16 2.01 
PLPP-032 818.54 20.463 9.508 2.15 2.23 
PLPP-040 849.61 21.24 9.974 2.13 2 
PLPP-063 1088.13 27.203 12.937 2.1 2.21 
PLPP-013 961.26 24.032 11.108 2.16 2.09 
PLPP-25 785.04 19.626 9.074 2.16 1.64 
PLPP-51 1692.65 42.316 19.736 2.14 2.23 
PLPP-52 1261.48 31.537 14.807 2.13 2.25 
PLPP-60 663.22 16.58 7.646 2.17 2.2 
PLPP-124 860.03 21.501 9.738 2.21 2.26 
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Figure 5.1   NanoDrop report for control samples. UV absorption plot has been shown for 
two sequential elutions. The top five curves indicate the first RNA elutions which were used 
in the microarray analysis while the lower ones are for the second RNA elutions. 
 
 
 
5.3. Bioanalyzer results 
All the samples included in the microarray analysis had RINs ranging from 5.70 to 7.30 
(Figure 5.2). 
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Figure 5.2   Electropherogram of samples included in microarray assay. 
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The placenta samples which were collected after vaginal delivery with a 1-6 hour delay until 
collection showed poor RNA quality despite using the same methodology in processing the 
samples and RNA extraction. The RIN for all these samples was below 5 (Figure 5.3) – 
therefore, these were not suitable for further evaluation. 
 
Figure 5.3   Bioanalyzer result for two of the placenta samples from vaginal delivery. 
  
 
 
The importance of using RNALater in maintaining the quality of RNA was illustrated when 
we compared the electropherograms of placental samples which were stored at -80°C in 
RNALater (n=4) to samples which were only stored at -80°C in normal saline (n=4). An 
example of this is illustrated in Figure 5.4. 
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Figure 5.4   Comparison of the RNA quality in samples stored in saline with those stored in 
RNALater (kept at -80°C). The electropherograms in each row are for the same sample. 
Saline RNALater 
  
  
 
 
Moreover, in our experiment the RNA concentration and quality was better when the RNA 
extraction was performed using TRIzol compared to a lysis buffer which was provided in the 
PureLink RNA Mini Kit. 
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5.4. Microarray gene results 
5.4.1. Quality control 
To assess the sample labelling reaction we applied the labelling metrics which showed 
increasing concentrations of lys, phe, and dap. This pattern ensures the correct labelling of the 
biological samples (Figure 5.5). 
 
Figure 5.5   Labelling controls. 
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BioB, BioC, BioD and cre, used as hybridization controls, showed increasing concentrations, 
indicating that hybridization had occurred correctly in all arrays (Figure 5.6). 
 
Figure 5.6   Hybridization controls. 
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The abundance of signal at 3’ end over the abundance of signal at 5’ end for GAPDH was less 
than 2 in all samples. A ratio less than 3 ensures the high quality of the samples included in 
microarray (Figure 5.7). 
 
Figure 5.7   3’/5’ ratio metrics. 
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5.4.2. Principle components analysis 
PCA was applied to have a visual measurement of the transcriptomic variation with regards to 
birth weight. There was relatively clear separation between FGR and control groups whereas 
macrosomic samples did not show a strict separation with either FGR or control groups 
(Figure 5.8). 
 
Figure 5.8   PCA plot in three weight groups. 
 
Red: FGR; Blue: Control; Green: Macrosomia. 
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5.4.3. Effect size 
A comparison of the amount of sample noise to absolute difference in gene expression was 
made using the ANOVA test to calculate p-values and the F-Ratio for effect sizes (Figure 
5.9). On the basis of differences in birth weight, absolute variance in gene expression was 
twice the level of background noise variance. 
 
Figure 5.9   The effect size of the fetal birth weight on transcriptome overall. 
 
 
 
5.4.4. Microarray gene expression analysis 
Transcriptomic profiling was performed in fifteen human placental samples collected from 
four FGR, six macrosomic and five control pregnancies. Quantitative microarray analysis of 
the gene expression dynamic in the three study groups was accomplished by applying 
ANOVA-based analysis. Significant changes in gene expression between FGR and control 
samples were seen with 242 transcripts (representing 199 genes) being up-regulated and 191 
transcripts (139 genes) down-regulated. Fewer significant changes were found when 
comparing macrosomic and control specimens with 42 transcripts (representing 33 genes) and 
10 transcripts (representing 8 genes) being up-regulated and down-regulated respectively. 
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The details of altered genes in each group and their changes in the opposite group are shown 
in tables 5.3 to 5.6. The most significant down-regulated genes in FGR pregnancies were 
TXNDC5 (fold change, F= -7.17; p=0.02), AREG (F= -3.72; p=0.01), LRRFIP1 (F= -3.56; 
p<0.01) and LRP2 (F= -3.35; p<0.01) (Table 5.3). Genes with significantly increased 
expression in placentas of FGR were also detected including CPXM2 (F= 6.2; p<0.01), 
RAB3B (F= 5.6; p=0.02), and GNGT1 (F= 5.6; p<0.01) (Table 5.4). In macrosomic newborns 
leptin (LEP) showed 6.5 fold down-regulation (p=0.01) and PHLDB2 showed 3.5 fold up-
regulation (p=0.02) (Table 5.5). Variants of GCH1 were also down-regulated (F= -2.4; 
p=0.02) (Table 5.6). 
 
In order to see the data spread in groups and provide a visual comparison between groups 
based on the signal intensity of individual samples, dot plots are shown for some selected 
genes (Figures 5.10 and 5.11). 
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Table 5.3   Down-regulated genes in FGR. 
Gene 
Symbol 
Gene Title 
Fold-
Change 
(FGR) 
p-value 
(FGR) 
Fold-
Change 
(Macro-
somia) 
p-value 
(Macro-
somia) 
MUTED 
/TXNDC5 
muted homolog (mouse) / thioredoxin domain containing 
5 (endoplasmic reticulum 
-7.2 0.021 -1.3 0.729 
AREG amphiregulin -3.7 0.012 -1.6 0.242 
LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 -3.6 0.000 -1.3 0.197 
LRP2 low density lipoprotein receptor-related protein 2 -3.4 0.003 -1.8 0.074 
FAM46C family with sequence similarity 46, member C -3.2 0.013 -2.3 0.040 
FRAS1 Fraser syndrome 1 -3.1 0.001 -1.6 0.065 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 -3.0 0.048 -2.1 0.121 
SIPA1L2 signal-induced proliferation-associated 1 like 2 -3.0 0.009 -1.6 0.183 
ENPEP glutamyl aminopeptidase (aminopeptidase A) -3.0 0.001 -1.3 0.187 
FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) -2.9 0.031 -1.5 0.299 
PPFIBP1 PTPRF interacting protein, binding protein 1 (liprin beta 1) -2.8 0.001 -1.4 0.150 
PTPRB protein tyrosine phosphatase, receptor type, B -2.8 0.002 -1.9 0.017 
TMEM97 transmembrane protein 97 -2.8 0.001 -1.5 0.087 
EGR1 early growth response 1 -2.8 0.047 -1.3 0.593 
ADAMTS19 ADAM metallopeptidase with thrombospondin type 1 
motif, 19 
-2.7 0.002 -1.1 0.704 
SOX4 SRY (sex determining region Y)-box 4 -2.7 0.036 -1.5 0.304 
SPATS2 spermatogenesis associated, serine-rich 2 -2.7 0.006 -1.4 0.235 
GCH1 GTP cyclohydrolase 1 -2.7 0.021 -2.3 0.029 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) -2.7 0.029 -1.3 0.438 
MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2, methenyltetrahydrof 
-2.6 0.015 -1.3 0.358 
ITGA6 integrin, alpha 6 -2.6 0.021 -1.3 0.425 
CHN1 chimerin (chimaerin) 1 -2.6 0.028 -1.4 0.347 
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 -2.6 0.006 -1.4 0.183 
GPD1L glycerol-3-phosphate dehydrogenase 1-like -2.5 0.019 -1.7 0.130 
PLK2 polo-like kinase 2 -2.5 0.017 -1.5 0.176 
BIN2 bridging integrator 2 -2.5 0.008 -1.6 0.116 
MAL2 mal, T-cell differentiation protein 2 -2.5 0.007 -1.4 0.264 
KIAA0101 KIAA0101 -2.5 0.015 -1.4 0.283 
JAG1 jagged 1 -2.5 0.037 -1.8 0.121 
ATP7B ATPase, Cu++ transporting, beta polypeptide -2.5 0.017 -1.1 0.690 
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Table 5.4   Up-regulated genes in FGR. 
Gene 
Symbol 
Gene Title 
Fold-
Change 
(FGR) 
p-value 
(FGR) 
Fold-
Change 
(Macro-
somia) 
p-value 
(Macro-
somia) 
CPXM2 carboxypeptidase X (M14 family), member 2 6.2 0.003 2.0 0.158 
RAB3B RAB3B, member RAS oncogene family 5.6 0.015 2.3 0.152 
GNGT1 guanine nucleotide binding protein (G protein), gamma 
transducing activity polyp 
5.6 0.005 3.3 0.022 
HERC2P2 
/HERC2P3 
hect domain and RLD 2 pseudogene 2 / hect domain and 
RLD 2 pseudogene 3 
4.3 0.044 2.4 0.168 
CLDN1 claudin 1 4.2 0.013 2.9 0.035 
SH3TC2 SH3 domain and tetratricopeptide repeats 2 3.9 0.008 3.5 0.007 
ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 3.5 0.011 2.2 0.062 
ZNF117 zinc finger protein 117 3.4 0.019 3.0 0.019 
C11orf90 chromosome 11 open reading frame 90 3.3 0.037 1.9 0.202 
MUC1 mucin 1, cell surface associated 3.3 0.006 -1.0 0.919 
FGF12 fibroblast growth factor 12 3.2 0.020 2.2 0.063 
LOC388948 hypothetical LOC388948 3.2 0.030 2.7 0.038 
TRPV6 transient receptor potential cation channel, subfamily V, 
member 6 
3.1 0.023 2.3 0.062 
NIPAL1 NIPA-like domain containing 1 3.1 0.042 2.2 0.109 
MUC15 mucin 15, cell surface associated 3.1 0.036 2.1 0.111 
ARHGEF37 Rho guanine nucleotide exchange factor (GEF) 37 3.1 0.039 1.6 0.325 
FHL1 four and a half LIM domains 1 3.0 0.045 1.5 0.413 
CD200 CD200 molecule 3.0 0.047 1.8 0.229 
RAB6B RAB6B, member RAS oncogene family 3.0 0.048 1.4 0.428 
SLC2A11 solute carrier family 2 (facilitated glucose transporter), 
member 11 
2.9 0.050 2.1 0.118 
RAB11FIP5 RAB11 family interacting protein 5 (class I) 2.9 0.042 1.5 0.331 
AFF1 AF4/FMR2 family, member 1 2.9 0.017 1.9 0.083 
FRZB frizzled-related protein 2.9 0.037 2.6 0.038 
FAM47E family with sequence similarity 47, member E 2.9 0.046 2.0 0.135 
AHR aryl hydrocarbon receptor 2.9 0.023 1.7 0.178 
PAPP-A pregnancy-associated plasma protein A, pappalysin 1 2.9 0.018 2.0 0.071 
HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 2.9 0.046 2.2 0.085 
STEAP4 STEAP family member 4 2.8 0.034 1.5 0.285 
TRAJ17 T cell receptor alpha joining 17 2.8 0.023 1.5 0.258 
MORN3 MORN repeat containing 3 2.8 0.046 1.4 0.397 
STAT5B signal transducer and activator of transcription 5B 2.7 0.029 1.8 0.142 
FURIN furin (paired basic amino acid cleaving enzyme) 2.7 0.016 1.7 0.115 
    Continued 
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Table 5.4   Continued 
Gene 
Symbol 
Gene Title 
Fold-
Change 
(FGR) 
p-value 
(FGR) 
Fold-
Change 
(Macro-
somia) 
p-value 
(Macro-
somia) 
PLAC4 placenta-specific 4 2.7 0.033 2.2 0.053 
PHLDB2 pleckstrin homology-like domain, family B, member 2 2.7 0.048 2.2 0.076 
SLC43A2 solute carrier family 43, member 2 2.7 0.000 1.8 0.005 
TMEM54 transmembrane protein 54 2.7 0.007 1.2 0.442 
SCNN1B sodium channel, nonvoltage-gated 1, beta 2.7 0.031 1.4 0.410 
MMP11 matrix metallopeptidase 11 (stromelysin 3) 2.7 0.041 1.9 0.109 
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 
2, neuro/glioblastoma 
2.7 0.040 1.7 0.205 
HIST1H1C histone cluster 1, H1c 2.6 0.036 1.7 0.169 
CAPN6 calpain 6 2.6 0.013 1.5 0.218 
SLC7A5 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 5 
2.6 0.047 1.5 0.287 
IGHA1 / 
IGHA2 
immunoglobulin heavy constant alpha 1 / 
immunoglobulin heavy constant alpha 2  
2.6 0.044 1.6 0.219 
C2orf72 chromosome 2 open reading frame 72 2.6 0.047 1.8 0.145 
SLC23A2 solute carrier family 23 (nucleobase transporters), 
member 2 
2.6 0.042 1.8 0.134 
CORO6 coronin 6 2.5 0.021 1.6 0.150 
DUSP4 dual specificity phosphatase 4 2.5 0.013 1.6 0.139 
ELF3 E74-like factor 3 (ets domain transcription factor, 
epithelial-specific ) 
2.5 0.025 1.5 0.253 
KIR2DL1 / 
KIR2DL2 
killer cell immunoglobulin-like receptor, two domains, 
long cytoplasmic tail, 1  
2.5 0.030 1.4 0.302 
STRA6 stimulated by retinoic acid gene 6 homolog (mouse) 2.5 0.050 1.9 0.125 
PCDH1 protocadherin 1 2.5 0.021 1.4 0.282 
ITPRIP inositol 1,4,5-triphosphate receptor interacting protein 2.5 0.017 1.5 0.213 
PAPP-A2 pappalysin 2 2.5 0.040 1.0 0.902 
TTBK2 tau tubulin kinase 2 2.5 0.020 1.5 0.181 
BLID BH3-like motif containing, cell death inducer 2.5 0.009 1.7 0.057 
KIAA1549 KIAA1549 2.5 0.010 1.1 0.808 
PLEKHA6 pleckstrin homology domain containing, family A member 
6 
2.5 0.050 1.6 0.252 
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Table 5.5   Down-regulated genes in macrosomia. 
Gene 
Symbol 
Gene Title 
Fold-Change 
(Macrosomia) 
p-value 
(Macrosomia) 
Fold-Change 
(FGR) 
p-value 
(FGR) 
LEP leptin -6.5 0.014 4.3 0.065 
COL17A1 collagen, type XVII, alpha 1 -4.3 0.049 -1.8 0.458 
HTRA4 HtrA serine peptidase 4 -3.1 0.024 -2.0 0.166 
BTNL9 butyrophilin-like 9 -2.9 0.022 -2.5 0.065 
HLA-DPB1 major histocompatibility complex, class II, DP 
beta 1 
-2.4 0.025 -1.9 0.119 
FAM46C family with sequence similarity 46, member C -2.3 0.040 -3.2 0.013 
GFRA2 GDNF family receptor alpha 2 -2.3 0.011 -2.2 0.021 
GCH1 GTP cyclohydrolase 1 -2.3 0.029 -2.7 0.021 
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Table 5.6   Up-regulated genes in macrosomia. 
Gene 
Symbol 
Gene Title 
Fold-
Change 
(Macro-
somia) 
p-value 
(Macro-
somia) 
Fold-
Change 
(FGR) 
p-value 
(FGR) 
PHLDB2 pleckstrin homology-like domain, family B, member 2 3.5 0.023 2.4 0.123 
SH3TC2 SH3 domain and tetratricopeptide repeats 2 3.5 0.007 3.9 0.008 
GNGT1 guanine nucleotide binding protein (G protein), gamma 
transducing activity polyp 
3.3 0.022 5.6 0.005 
C15orf29 chromosome 15 open reading frame 29 3.1 0.004 2.0 0.077 
ZNF117 zinc finger protein 117 3.1 0.011 2.6 0.039 
CLDN1 claudin 1 2.9 0.035 4.2 0.013 
LPHN3 latrophilin 3 2.7 0.025 2.4 0.060 
LOC388948 hypothetical LOC388948 2.7 0.038 3.2 0.030 
FRZB frizzled-related protein 2.6 0.038 2.9 0.037 
FAM164A family with sequence similarity 164, member A 2.6 0.005 1.4 0.248 
C10orf118 chromosome 10 open reading frame 118 2.5 0.049 2.1 0.125 
USP16 ubiquitin specific peptidase 16 2.4 0.007 2.2 0.022 
GOLGA4 golgin A4 2.4 0.033 1.9 0.151 
MALAT1 metastasis associated lung adenocarcinoma transcript 1 
(non-protein coding) 
2.4 0.025 2.4 0.043 
FGF7 fibroblast growth factor 7 2.4 0.020 1.6 0.217 
C14orf106 chromosome 14 open reading frame 106 2.3 0.029 1.4 0.423 
SMC3 structural maintenance of chromosomes 3 2.3 0.008 1.6 0.115 
ZNF554 zinc finger protein 554 2.3 0.014 2.2 0.030 
DEPDC1B DEP domain containing 1B 2.2 0.048 2.2 0.076 
FER1L4 fer-1-like 4 (C. elegans) pseudogene 2.2 0.014 2.1 0.036 
STRA6 stimulated by retinoic acid gene 6 homolog (mouse) 2.2 0.050 2.5 0.039 
PPIG peptidylprolyl isomerase G (cyclophilin G) 2.2 0.040 1.3 0.444 
CASP4 caspase 4, apoptosis-related cysteine peptidase 2.1 0.028 1.2 0.595 
DST dystonin 2.1 0.016 1.3 0.401 
ATRX alpha thalassemia/mental retardation syndrome X-linked 2.1 0.034 1.5 0.308 
GABRE gamma-aminobutyric acid (GABA) A receptor, epsilon 2.1 0.006 1.9 0.020 
ISM1 isthmin 1 homolog (zebrafish) 2.1 0.007 1.4 0.191 
ZNF644 zinc finger protein 644 2.1 0.003 1.7 0.028 
PHIP pleckstrin homology domain interacting protein 2.1 0.024 1.4 0.263 
USP15 ubiquitin specific peptidase 15 2.0 0.018 2.3 0.013 
GCC2 GRIP and coiled-coil domain containing 2 2.0 0.015 1.7 0.075 
SMC4 structural maintenance of chromosomes 4 2.0 0.026 -1.0 0.981 
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Figure 5.10   Dot plots for some of the dysregulated genes in FGR. 
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Figure 5.10   Continued   
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Figure 5.10   Continued   
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Figure 5.10   Continued   
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Figure 5.10   Continued   
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Figure 5.11   Dot plots for some of the dysregulated genes in macrosomia. 
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Figure 5.11   Continued   
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The bioinformatics analyses of the data suggested the disturbance of various molecular and 
cellular functions and their links to diseases. Differential gene expression in FGR was most 
strongly associated with nervous system development, organismal development, cell-to-cell 
signalling and interaction network functions. Differential gene expression in macrosomic 
newborns was most strongly associated with nutritional disease, behaviour, digestive system, 
lipid metabolism development and function and cell-to-cell signalling and interaction network 
functions. Genes that were significantly differentially expressed in FGR included groups 
associated with gastrointestinal disease (p<0.001), haematological disease (p<0.001), 
endocrine system disorders (p<0.001), and neurological disease (p<0.001). Genes that were 
significantly differentially expressed in macrosomic newborns included groups associated 
with nutritional disease (p<0.001), psychological disorders (p<0.001), cardiovascular disease 
(p<0.001) and connective tissue disorders (p<0.001). 
 
Lipid metabolism was altered in both groups with significant changes in 34 molecules in FGR 
(p<0.001) and in 3 molecules (p<0.001) in the macrosomic group. Significant dysregulation 
of the canonical epithelial-mesenchymal transition pathway (p<0.001) was seen in FGR. 
Genes involved in this group included FGFR3, MET, ETS1, PIK3C2B, APH1B, EGR1, 
FGF12, FGFR2, FZD5, JAG1, TCF7L2, and EGFR. The Notch signalling pathway also 
showed significant changes in FGR (p<0.001) with alterations in the expression of NOTCH2, 
FURIN, APH1B, and JAG1. Upstream analysis in FGR indicated that p53 (activation z-
score=2.002; p<0.001) was activated. As there were fewer up- / down-regulated genes defined 
in the macrosomic group, pathway analysis showed no significant changes. At a single gene 
level GCH1, part of the tetrahydrobiopterin biosynthesis pathway showed significant down-
regulation (p<0.001). Potential biomarkers identified through bioinformatics analysis are 
shown in table 5.7 and 5.8. 
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Table 5.7   Potential biomarkers that are up- or down-regulated in placental tissue from term 
growth restricted newborns. 
Symbol Location / Family Affymetrix Probe ID Folds Change p-value 
Potential biomarkers that are up-regulated    
CPXM2 Extracellular space / Peptidase 11719536_at 6.2 <0.01 
CLDN1 Plasma membrane 11728234_a_at 4.2 0.001 
ST3GAL1 Cytoplasm / Enzyme 11718738_a_at 3.5 0.001 
TRPV6 Plasma membrane / Ion channel 11752375_a_at 3.1 0.02 
CD200 Plasma membrane 11742863_a_at 3.0 0.05 
 Potential biomarkers that are down-regulated    
TXNDC5 Cytoplasm / Enzyme 11715395_a_at -7.2 0.02 
LRRFIP1 Cytoplasm 11739298_a_at -3.6 <0.001 
LRP2 Plasma membrane / Transporter 11727123_at -3.4 <0.01 
ENPEP Plasma membrane / Peptidase 11721126_a_at -3.0 <0.001 
PPFIBP1 Plasma membrane 11734874_x_at -2.8 <0.001 
 
 
Table 5.8   Potential biomarkers that are up- or down-regulated in placental tissue from term 
macrosomic newborns. 
Symbol Location / Family Affymetrix Probe ID Folds Change p-value 
Potential biomarkers that are up-regulated 
PHLDB2 Cytoplasm 11737039_a_at 3.5 0.02 
C15orf29 Nucleus 11761552_at 3.1 <0.01 
CLDN1 Plasma membrane 11728234_a_at 2.9 0.03 
LPHN3 Plasma membrane 11726897_s_at 2.7 0.02 
Potential biomarkers that are down-regulated 
LEP Extracellular space / Growth factor 11735095_at -6.5 0.01 
COL17A1 Plasma membrane 11726564_a_at -4.3 0.05 
GCH1 Cytoplasm / Enzyme 11721733_a_at -2.3 0.03 
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Chapter 6 
Discussion 
6.1 Summary 
We aimed to determine whether there was evidence of functional placental pathology 
underlying abnormal fetal growth and development by performing global gene expression 
analysis. We have demonstrated that there are a significant number of genes that are 
differentially expressed in either FGR or macrosomic pregnancies. Genes associated with 
abnormal fetal growth that may play a role in the fetal origin of adult onset diseases were 
described. Genes that were differentially expressed differed between FGR and macrosomia so 
the developmental mechanisms associated with these changes are unlikely to merely represent 
opposite ends of a spectrum. 
 
6.2 Optimising the placenta sample collection and RNA extraction 
Experiments that were performed to define the optimal method for collecting and storing 
placental samples for RNA extraction and gene expression analysis showed that whilst tissues 
collected at the time of elective Caesarean section were of good quality, those collected at the 
time of vaginal delivery were of poor quality and were not suitable for further analysis. One 
significant difference in the collection protocols was that the researcher was present at the 
time of Caesarean section and all samples were processed in <20 minutes. In contrast, the 
researcher was telephoned to attend after vaginal delivery, leading to a delay of 1-6 hours in 
sample preparation. Further work is needed to demonstrate whether this time delay is the 
major reason for sample failure or whether the poor sample quality is inherent in the process 
of vaginal delivery. This will require the presence of research staff on the labour ward at the 
time of delivery. This is important to assess, as in the long term it is important to determine 
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placental function in a cohort (the majority of pregnancies) that have vaginal delivery as well 
as from those women having a Caesarean section. 
 
Sitras et al. investigated the effect of the mode of labouring on gene expression in near term 
human placentas. The analysis 27 placenta samples after vaginal delivery and 17 samples 
after elective Caesarean section showed 92 genes were down-regulated and 94 genes were up-
regulated in the placentas obtained from vaginal delivery compared to those from Caesarean 
section. However, all these genes expressed at a level of <2.5 fold-change and p>0.01 (Sitras 
et al., 2008). 
 
Fajardy et al. evaluated the RNA quality by performing a set of experiment on human 
placenta over a progressive time course of 4 days. They used two different protocols which 
included direct transfer of tissue into RNALater and a dissection of placenta villosities before 
bio-banking. The findings showed that placental samples can be stored at 4°C up to 48 hours 
without alteration in RNA quality. The result of RNA integrity and intensity testing was better 
in those tissues that were directly transferred to RNALater solution (RIN ranged from 6.44 to 
7.22) compared with those that underwent a dissection before RNA processing (RIN ranged 
from 4.5 to 6.05). Long term storage of the placenta did not affect RNA integrity except for 
changes in the transcript levels of stress-responsive genes such as TNF-alpha and COX2 after 
48 hours (Fajardy et al., 2009). 
 
6.3 Investigation of the microarray findings 
The 41 genes found to be differentially expressed in macrosomic newborns contribute to 
various molecular and biological functions with possible long term implications. The 
expression of leptin (LEP) was six times lower in macrosomic placentas compared to 
 
     88 
controls. Sialic acid binding Ig-like lectin 6 (SIGLEC6), that binds to and modulates leptin, 
was also marginally down-regulated (F= -1.9, p=0.085). Leptin, a 167-amino-acid peptide, is 
mainly produced in adipose tissue and is involved in the control of hypothalamic-pituitary-
gonadal axis (Zhang et al., 1994). Most leptin effects seem to be mediated through specific 
counteraction of neuropeptide Y (NPY) in the hypothalamus (Wiznitzer et al., 2000). The 
leptin receptor is abundantly expressed in the arcuate nucleus of the hypothalamus which 
makes it a target site for leptin induced effects (Figure 6.1) (Kageyama et al., 2012). This 
protein plays a crucial role in the endocrine regulation of appetite, energy homeostasis and 
insulin secretion. In adults, the serum concentration of leptin is inversely proportional to body 
fat mass and is sometimes referred to as the obesity gene (Considine et al., 1996). Leptin is 
also associated with control of blood pressure, bone formation, immunity and reproductive 
developmental changes. Dysregulation in fetal life has the potential to have a significant 
impact on a child’s long term development (Shekhawat et al., 1998). 
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Figure 6.1 Adipocytokine signalling based on the KEGG pathways in human. 
Source: http://www.kegg.jp  
 
 
Some studies have measured leptin levels in maternal and cord blood with regards to fetal 
growth (Table 6.1 and 6.2) but there are a few studies on global gene expression analysis of 
placenta in the pregnancies affected by FGR or macrosomia. Despite some variances in the 
results of different studies the consensus appears to be that cord blood leptin increases in 
macrosomia but decreases in FGR while there are no significant changes in the maternal 
blood of macrosomic and growth restricted newborns. Interestingly, the changes seen in leptin 
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gene expression oppose those seen in the concentration of leptin in cord blood, suggesting 
that the regulatory mechanisms involving in translating gene into protein expression are 
complex. Investigation of leptin expression has shown that the leptin levels in macrosomic 
infants is higher than in controls and that there are higher levels in infants of diabetic mothers 
when compared to non-diabetic mothers (Vela-Huerta et al., 2008). 
 
Table 6.1   Findings of other studies showing the changes in leptin level in maternal blood, 
cord blood, and placenta in FGR. 
Reference Assay 
Maternal 
blood 
Cord 
blood 
Placental 
gene 
expression 
(Struwe et al., 2010) Microarray, Radioimmunoassay - = ↑ 
(Valuniene et al., 2007) Radioimmunoassay - ↓ - 
(Martinez-Cordero et al., 2006) Immunoradiometric assay - ↓ - 
(Weyermann et al., 2006) ELISA = ↓ - 
(Grisaru-Granovsky et al., 2003) Immunoradiometric assay = = - 
(Pighetti et al., 2003) Immunoradiometric assay ↑ ↓ - 
(Yildiz et al., 2002) Radioimmunoassay ↓ ↓ - 
(Varvarigou et al., 1999) Radioimmunoassay = ↓ - 
(Koistinen et al., 1997) Radioimmunoassay - ↓ - 
 
 
Table 6.2   Findings of other studies showing the changes in leptin level in maternal blood, 
cord blood, and placenta in macrosomia. 
Reference Assay 
Maternal 
blood 
Cord 
blood 
Placental gene 
expression 
(Ategbo et al., 2006) ELISA ↑ - - 
(Weyermann et al., 2006) ELISA ↓ = - 
(Mazaki-Tovi et al., 2005a) Radioimmunoassay - ↑ - 
(Yang and Kim, 2000) Immunoradiometric assay - ↑ - 
(Varvarigou et al., 1999) Radioimmunoassay ↑ ↑ - 
(Shekhawat et al., 1998) Radioimmunoassay - ↑ - 
(Koistinen et al., 1997) Radioimmunoassay - ↑ - 
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Leptin together with ten other focussed molecules including ATRX, CASP4, FGF7, FRZB, 
GCH1, GFRA2, GNGT1, PHIP, PPIG, and SMC3 was involved in a network that contributes 
to digestive system development and function (Figure 6.2). Disturbance of this network 
postulates a higher risk for nutritional disease and behavioural disorders in the macrosomic 
group. 
 
In our dataset, while leptin was significantly increased in macrosomic newborns, a 
comparison between diabetic and non-diabetic mothers did not show any difference in gene 
expression. This finding is conflictive with the literature, and may be due to the small number 
of samples available in this series. Alternatively there may be no difference due to the high 
standard of blood glucose control documented in these pregnancies. 
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Figure 6.2   Network of molecules including leptin which play a role in digestive system 
development. Focused molecules in this study have been highlighted. Red colour indicates the 
up-regulated and green colour indicates the down-regulated genes in macrosomia. 
 
 
 
Guanosine triphosphate cyclohydrolase I (GCH1) was shown to be down-regulated in both 
FGR (F= -2.7, p=0.02) and macrosomia (F= -2.3, p=0.03). The protein encoded by GCH1 is 
the first and rate-limiting enzyme in tetrahydrobiopterin (BH4) biosynthesis which is an 
essential cofactor required by aromatic amino acid hydroxylases and nitric oxide synthases. 
Inhibition or silencing of GCH1 reduces the tube formation of human umbilical vein 
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endothelial cells (Pickert et al., 2013). Therefore, decreased GCH1 production in FGR can 
result in reduced levels of nitric oxide and hence, disturbance of endothelial cell formation of 
the umbilical cord leading to abnormal fetal growth due to improper nutrient and waste 
transfer. BH4 is essential for synthesis of dopamine, norepinephrine, epinephrine, and 
serotonin (Kapatos, 2013). BH4 deficiency has been described in severe neurological 
disorders and is also implicated in Parkinson's disease, Alzheimer's disease and depression 
(Figure 6.3) (Thony et al., 2000, Blau et al., 2001). 
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Figure 6.3   Serotonin receptor signalling. GCH1 catalyses the production of BH4, a required 
cofactor in the synthesis of serotonin. GCH1 had decreased level of expression in both FGR 
and macrosomia. 
 
 
  
 
     95 
In FGR, 73 dysregulated genes had a role in embryonic development. Development of 
sensory organs (activation z-score=1.13, p<0.001), structures of the head and neck (activation 
z-score= 1.20, p<0.001), the size of the embryo (activation z-score= -3.18, p<0.001), and eye 
development (activation z-score=1.13, p<0.001) were the top physiological functions affected 
in FGR. 21 genes with potential effect on the size of embryo were involved in this group. 
Based on the direction of the changes, eighteen were predictive for FGR, including CTNNB1, 
ETS2, F5, FGFR2, FLI1, FOXP1, ITGB8, LIMS1, LRP2, MAD2L1, MTHFD2, MYCN, 
NUSAP1, PARP1, PPP3R1, RECK, SPTBN1, and SOX4 while three were predictive of 
macrosomia; FURIN, EGFR, and HIST1H1C. 
 
The DAVID analysis for disease (online Mendelian inheritance in man (OMIM) category) 
identified higher risk for type 2 diabetes mellitus in FGR based on a meta-analysis of 
genome-wide association (p=0.01). Notch homolog 2 (Drosophila) (SBNO2), 
hematopoietically expressed homeobox (HHEX), leucine-rich repeat-containing G protein-
coupled receptor 5 (LGR5), transcription factor 7-like 2 (T-cell specific, HMG-box) 
(TCF7L2) were recognised as genes related to a susceptibility for type 2 diabetes. The 
DAVID pathway viewer identified significant clusters of Kyoto Encyclopaedia of Genes and 
Genomes (KEGG), PANTHER, and REACTOME pathways in FGR (Table 6.3) but because 
of the limited number of genes involved in the macrosomic group no significant biological 
pathways were defined. 
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Table 6.3   Significant cluster of pathways in three different categories related to growth 
retardation. 
Category Term Count p-value 
KEGG_PATHWAY hsa04320: Dorso-ventral axis formation 5 <0.01 
KEGG_PATHWAY hsa04520: Adherens junction 6 0.02 
    
PANTHER_PATHWAY P00005: Angiogenesis 11 <0.01 
PANTHER_PATHWAY P04398: p53 pathway feedback loops 2 5 0.04 
PANTHER_PATHWAY P00004: Alzheimer disease-presenilin pathway 8 0.04 
    
REACTOME_PATHWAY REACT_299: Signalling by Notch 4 <0.01 
REACTOME_PATHWAY REACT_578: Apoptosis 8 0.03 
REACTOME_PATHWAY REACT_13: Metabolism of amino acids 9 0.03 
REACTOME_PATHWAY REACT_15518: Transmembrane transport of small molecules 4 0.07 
 
 
Notch Signalling was one of the top canonical pathways affected in FGR (p<0.01). Four 
genes in this network had disturbed levels of expression; two being up-regulated and two 
down-regulated (Table 6.2 and Figure 6.4). 
 
Table 6.2   Genes associated with Notch signalling in FGR. 
Symbol Fold Change p-value Location/Type 
FURIN 2.7 0.02 Cytoplasm/Peptidase 
NOTCH2 2.0 0.01 Plasma membrane/Transcription regulator 
APH1B (Gamma-Secretase) -2.1 0.03 Plasma membrane/Peptidase 
JAG1 -2.5 0.04 Extracellular space/Growth factor 
 
 
The Notch pathway is involved in cell fate choices in various developing tissues and it is an 
evolutionarily conserved mechanism for cell-cell interaction. Mouse models have 
demonstrated this pathway is crucial for various processes happening during placental 
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development such as fetal angiogenesis and formation of maternal blood vessels in the 
placenta (Gasperowicz and Otto, 2008). 
 
Figure 6.4   Notch signalling pathway and dysregulated genes in FGR. 
 
 
 
ErbB signalling was also affected in FGR with involving six genes including AREG/AREGB, 
EGFR, ERBB2, FOS, PAK3, and PIK3C2B (p<0.001). This pathway plays an important role 
during growth and development of a number of tissues including the heart, mammary gland 
and the central nervous system. 
 
Abnormal level of the expression of BCL2, CCNG1, CTNNB1, PIK3C2B, PMAIP1, and TP63 
resulted in disturbance of p53 signalling in FGR (p<0.001). Upstream analysis in this group 
 
     98 
also showed the activation of p53. The p53 tumour suppressor protein is a transcriptional 
regulator that plays a crucial role in DNA repair, cell-cycle progression, angiogenesis, and 
apoptosis. 
 
In order to obtain functional classification of the dysregulated genes, we used the PANTHER 
online tool to investigate the pathways and biological processes that these genes contribute to 
(Mi and Thomas, 2009, Mi et al., 2010). In FGR, the most significant pathway distinguished 
based on PANTHER database was angiogenesis (Figure 6.5) with involvement of 11 genes 
including protein jagged-1 (JAG1), neurogenic locus notch homolog protein 2 (NOTC2), p21 
protein-activated kinase 3 (PAK3), receptor-type tyrosine-protein phosphatase beta (PTPRB), 
transcription factor 7-like 2 (TF7L2), frizzled-5 (FZD5), v-Ets avian erythroblastosis virus 
E26 oncogene homolog 1 (ETS1), frizzled-related protein (FRZB), catenin beta-1 (CTNNB1), 
phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta (P3C2B), 
proto-oncogene c-fos (FOS). 
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Figure 6.5   Pathways affected in FGR based on PANTHER database. 
 
EGF, epidermal growth factor; FGF, fibroblast growth factor; GnRH, gonadotropin releasing hormone, PDGF, platelet derived growth factor. 
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6.4 Other microarray studies on the placenta 
Different microarray studies have targeted the role of placenta in FGR and preeclampsia. 
Sitras et al. investigated the placental gene expression profile in FGR due to placental 
insufficiency. The study population included eight women with uncomplicated pregnancies 
and eight women with FGR. Three criteria were considered for the definition of FGR in this 
study: (a) birth weight below the ≤5th centile for gestational age; (b) oligohydramnios 
(amniotic fluid index 5
th
 centile for gestational age); and (c) abnormal fetal Doppler 
parameters (absent or reversed end-diastolic flow in the umbilical artery or signs of blood 
redistribution). One of the women with FGR and two controls had their babies delivered 
vaginally. Women with growth restricted fetuses but normal Doppler were excluded. Four of 
the FGR pregnancies were also affected by preeclampsia. The microarray procedure involved 
the ‘Applied Biosystems Chemiluminescent NanoAmp RT-IVT Labelling Kit’ followed by 
RT-PCR validation. The results of this study demonstrated 47 up-regulated and 70 down-
regulated genes with ≥1.5 fold changes and p≤0.05 compared to normal placentas (Table 6.4 - 
Study 1). Pathway analysis in this study showed up-regulation of inflammation mediated by 
the chemokine and cytokine signalling pathway. Transcription factors Fos and FosB which 
might regulate angiogenesis through mediators such as vascular endothelial growth factor and 
placental growth factor were up-regulated in FGR placenta by 2.5 fold. Down-regulated genes 
were mostly ribosomal protein coding genes, indicating reduced gene translation in FGR 
pregnancies. There was no significant difference in subgroup analysis between FGR placentas 
of pregnancies with and without preeclampsia, however common pathogenic mechanisms 
were observed with severe early-onset preeclampsia (Sitras et al., 2009). 
 
Struwe et al. performed a microarray study on the placenta of ten normal and ten growth 
restricted newborns. Birth weight <10
th
 percentile and at least one pathologic finding in 
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prenatal Doppler ultrasound were considered as FGR definition and infants with birth weight 
between 25 and 75 percentile were considered as controls. Both male and female infants were 
included in this multicentre study. Considering ≥2 folds change as being significant; 132 
genes were up-regulated and 25 were down-regulated. Four up-regulated genes with possible 
roles in prenatal and postnatal growth and with subsequent metabolic consequences were 
validated by RT-PCR including IGFBP-1, prolactin, leptin, and corticotropin releasing 
hormone (CRH). RT-PCR confirmed the higher expression of IGFBP-1, leptin, and CRH. 
However, on the protein level using western blot analyses, only IGFBP-1 and leptin showed 
higher expression in FGR. It has been suggested that leptin was positively correlated with 
feto-placental insufficiency in growth restricted newborns (Struwe et al., 2010). 
 
Nishizawa et al. performed a microarray study to investigate the mechanisms underlying 
preeclampsia and FGR using the Affymetrix GeneChip system. In this study, FGR was 
defined as birth weight <10
th
 percentile for gestational age. The analysis of eight 
preeclamptic, eight normotensive without FGR, and eight normotensive with FGR placentas 
suggested a high correlation coefficient between subset of FGR and preeclampsia but lack of 
concordance between normotensive and disease samples, indicating significant gene 
expression alteration upon the onset of preeclampsia and FGR. Notably, compared with 
preeclampsia, less FGR sample pair correlation was observed which reflects the possibility of 
heterogeneous pathophysiology of FGR. Changes in expression were defined by a 1.5 fold-
change and p<0.05; comparison between the control pregnancy and FGR group identified a 
total of 252 genes, including 62 genes in common with the gene set for preeclampsia (Table 
6.4 - Study 2). Gene set enrichment analysis revealed the activation of p53 pathway and 
placental anti-angiogenic factors in preeclampsia and FGR. Genes such as LEP, CGB, CRH, 
and PAPP-A2 were up-regulated in both FGR and preeclampsia (Nishizawa et al., 2011). 
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Interestingly, our data also showed a degree of the up-regulation of these genes in FGR as 
LEP (F=4.3, p=0.07), CGB (F=2.8, p=0.05), CRH (F=2.9, p=0.09), PAPP-A (F=2.9, p=0.02), 
and PAPP-A2 (F=2.5, p=0.04). Our findings confirmed p53 signalling pathway activation in 
FGR. 
 
Other studies have focused on the role of specific placental networks or metabolic processes 
in terms of fetal growth and development. Lee et al. performed gene expression analysis of 
the placenta to investigate the changes occurring in glucose metabolism in FGR using a 
‘Whole Human Genome Oligo Microarray Kit’ (Agilent). Tissue from six normal and six 
FGR from pregnancies >37 weeks’ gestational age delivered by Caesarean section were 
included. FGR pregnancies were diagnosed based on the findings of ultrasound scanning. 
2,012 genes had disturbed level of expression with ≥2 fold-change, of which seven had 
possible role in the metabolism of glucose including LDHC, DLAT, PFKFB2, OGDH, PYGM, 
PGM3, and IGF2 (Table 6.4 - Study 3) (Lee et al., 2010). Our results did not show significant 
changes in these genes, however other similar genes related to glucose metabolism such as 
IGF1R (F= -1.9, p<0.01), IGF2 (F= -1.9, p=0.05), IGF2BP2 (F=1.8, p=0.04), and IGFBP-7 
(F= -2, p=0.06) were observed. 
 
Toft et al. demonstrated changes in placental angiogenic genes in pregnancies affected by 
preeclampsia and FGR. Study groups included preeclampsia (n=10), FGR (n=8), and 
preeclampsia + FGR (n=10). Microarray results did not show significant difference however, 
two anti-angiogenic genes, endoglin (ENG) and fms related tyrosine kinase 1 (FLT1) have 
been reported to be increased in RT-PCR experiments in preeclampsia with FGR (Toft et al., 
2008). This study considered comparing preeclampsia and FGR without having normal 
control placentas and therefore it would be expected to see no significant difference in gene 
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expression pattern since these two pathological conditions might share similar 
pathophysiology. However, the authors have concluded that microarrays might not be 
sensitive enough to detect subtle changes in gene expression. 
 
Another study by Dunk et al. showed up-regulation of BTNL9 and NTRK2 in placental micro-
vascular endothelial cells in severe FGR placentas. Three preterm control placenta and six 
placentas from pregnancies with severe FGR from pregnancies between 24 to 34 weeks 
gestational age delivered vaginally or by Caesarean section were analysed using ‘Affymetrix 
U133 Plus 2 GeneChips’. Preterm controls were appropriately grown fetuses while severe 
FGR were defined as fetal weight ≤10th percentile with absent or reversed end-diastolic 
velocities in the umbilical artery (Dunk et al., 2012). Our results showed marginally 
significant down-regulation of BTNL9 (F= -2.4, p=0.06) in the placentas of macrosomic 
babies. 
 
Winn et al. suggested that leptin, CRH, inhibin, SIGLEC6, and PAPP-A2 are differentially 
expressed in severe preeclampsia. These findings were obtained from an array-based study 
using the HG-U133 Affymetrix GeneChip platform on 11 women who experienced 
preeclampsia and 12 preterm patients. 55 genes were identified as being differentially 
expressed and statistical analysis showed the method of delivery (vaginal delivery vs. 
Caesarean section) was not a confounding factor (Winn et al., 2009). Interestingly, the results 
of our study showed down-regulation of SIGLEC6 and LEP in macrosomic groups which 
support the possible common pathophysiology of abnormal fetal growth and preeclampsia 
through at least in some stages / forms of the diseases’ development. 
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Table 6.4   Data from other microarray studies on placenta showing up-regulated and down-
regulated genes in FGR. 
Up-regulated Genes  Down-regulated Genes 
Gene Name Fold-Change p-value Gene Name Fold-Change  p-value 
Study 1 (Sitras et al., 2009) Study 1 (Sitras et al., 2009)  
CYTL1 3.0 0.01 DHRS2 -2.9 0.05 
C7 2.9 <0.01 TRIM28 -2.8 0.02 
FOS  2.6 0.01 MGAT4B -2.7 <0.01 
FOSB  2.5 0.02 MBD3 -2.7 0.01 
EVI5 2.5 <0.01 PAQR7 -2.4 0.01 
HSD11B1 2.3 <0.01 HYAL2 -2.4 0.04 
LGALS14 2.3 0.02 ENG -2.3 0.01 
FKHL18 2.2 0.03 UNC13D -2.3 <0.01 
DKFZP564O0823 2.1 <0.01 MICAL-L1 -2.2 0.01 
FLJ20032 2.1 <0.01 TACSTD2 -2.2 0.03 
THOC2 2.0 <0.01 FBXW5 -2.2 <0.01 
RBP1 1.9 0.01 unassigned -2.1 0.03 
ADCY3 1.9 <0.01 MRPL39 -2.0 0.02 
ADAMTSL3 1.9 <0.01 PCQAP -2.0 <0.01 
B PTPRB 1.9 <0.01 TMEM16A -2.0 0.01 
RORA 1.9 <0.01 UBXD1 -2.0 <0.01 
ACTR2 1.8 0.02 PLEKHM2 -2.0 <0.01 
C8orf70 1.8 0.03 SRCAP -2.0 <0.01 
ALOX5AP 1.8 0.01 RAI16 -2.0 <0.01 
RTP2 1.8 0.03 S100A6 -2.0 <0.01 
SPRR2A 1.8 0.04 BCAR1 -2.0 <0.01 
VPREB3 1.8 0.04 YEATS4 -2.0 <0.01 
BRAP 1.8 0.01 CHPT1 -1.9 <0.01 
FAM26C 1.7 0.02 CSRP2 -1.9 <0.01 
LOC157860 1.7 0.03 DPP9 -1.9 0.02 
ZNF650 1.7 0.04 RPS10 -1.9 <0.01 
PTGER2 1.7 0.01 AREG -1.9 0.01 
GSTA5 1.7 0.01 SYDE1 -1.9 0.02 
PLCB1 1.7 0.03 ENTPD6 -1.9 <0.01 
     Continued 
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Table 6.4   Continued   
Up-regulated Genes  Down-regulated Genes 
Gene Name Fold-Change p-value Gene Name Fold-Change  p-value 
Study 1 (Continued) Study 1 (Continued)  
LTBP2 1.7 0.02 MOSC1 -1.9 <0.01 
ACTC 1.7 0.02 unassigned -1.9 0.02 
RRAS 1.7 0.01 RPL36A -1.9 <0.01 
KCNJ8 1.7 0.01 CHUK -1.9 0.01 
ETV3 1.7 0.01 CLDN23 -1.8 0.01 
TPRXL 1.6 0.01 BCORL1 -1.8 0.01 
CXCR4 1.6 0.01 ADORA2B -1.8 0.01 
RNF4 1.6 0.03 18 SLC22A18 -1.8 0.02 
PSCD3 1.6 0.03 LOC387758 -1.8 0.02 
GPX7 1.6 0.01 HNRPL -1.8 <0.01 
OSBPL3 1.6 0.01 NFE2L3 -1.8 0.01 
SAA3P 1.6 0.04 MTA2 -1.8 0.01 
ANKRD33 1.6 0.04 FAM3A -1.8 0.02 
DEFB1 1.6 0.01 PVRL2 -1.8 0.01 
FLJ16542 1.6 0.03 SCPEP1 -1.8 0.01 
NUDT10 1.6 0.02 SLITL2 -1.7 0.01 
SMOC2 1.5 0.03 ADAMTS19 -1.7 0.01 
MYST2 1.5 0.04 TMEM9 -1.7 0.01 
Study 2 (Nishizawa et al., 2011)  ACADS -1.7 0.01 
CXCL9 2.44 0.04 DDR1 -1.7 0.01 
KRTAP26 1.91 0.04 MLLT1 -1.7 0.01 
LOX 1.88 <0.01 SUPT5H -1.7 0.01 
CXCL13 1.74 0.02 SLC39A7 -1.7 0.04 
FPR3 1.73 0.04 RAB17 -1.7 0.01 
FLJ11827 1.71 0.01 SLC39A6 -1.7 0.03 
IFNG 1.70 0.02 CPOX -1.7 0.01 
RGS1 1.69 0.01 AP2A1 -1.7 0.02 
THBS1 1.90 <0.01 CDC20 -1.6 0.04 
GZMK 1.67 0.02 GPR157 -1.6 0.01 
CYR61 1.65 0.02 DUSP9 -1.6 0.02 
     Continued 
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Table 6.4   Continued   
Up-regulated Genes  Down-regulated Genes 
Gene Name Fold-Change p-value Gene Name Fold-Change  p-value 
Study 2 (Continued) Study 1 (Continued)  
MSR1 1.63 0.04 CD151 -1.6 0.02 
IFI44L 1.63 0.03 CHST2 -1.6 0.03 
TIMP1 1.62 0.03 COMMD8 -1.6 0.02 
C1QB 1.60 0.04 SIL1 -1.6 0.04 
Study 3* (Lee et al., 2010)  GLB1L -1.6 0.03 
LDHC 2.6 <0.01 C20orf22 -1.5 0.02 
OGDH 2.5 <0.05 LXN -1.6 0.04 
IGF2 2.4 <0.05 WDR42A -1.6 0.02 
PFKFB2 2.0 <0.01 FLJ20718 -1.6 0.04 
PYGM 2.0 <0.01 DOCK6 -1.5 0.04 
DLAT 1.9 <0.05 ACPP -1.5 0.04 
PGM3 1.8 <0.01 Study 2 (Nishizawa et al., 2011)  
   OR4F16 -1.85 0.02 
   RPS6KA6 -1.82 0.00 
   PCDH11Y -1.69 0.02 
   GABRE -1.64 0.03 
   MGC3536 -1.64 0.01 
   KIAA1467 -1.63 0.01 
   HIST1H2BK -1.61 0.02 
   GABRA4 -1.58 <0.01 
   LOC441233 -1.56 0.03 
   PGAP1 -1.55 <0.01 
   LRP2 -1.55 0.01 
   AGL -1.53 0.01 
   CCDC125 -1.53 <0.01 
   HYAL4 -1.53 0.01 
   C9orf131 -1.52 <0.01 
*This study focused on glucose metabolism-related genes.   
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6.5 Limitations of this study 
This study was based on a relatively small number of samples and was performed as a means 
to develop the technique with a view to allowing more involved assessment, using tissues 
from a larger cohort of pregnancies at a later date. Although significant changes in gene 
expression are seen we are mindful of the fact that the relatively small number of samples 
used here mean that the study is prone to bias. Some of this bias was removed by ensuring 
similarity in samples used in the experiments; controlling for mode of the delivery, sex of the 
babies, and gestational age to avoid the effect of some known confounders. Moreover, based 
on power analysis, only genes with two or more fold changes were selected for downstream 
analysis to achieve more reliable results. 
 
Defining the study groups especially FGR was the other challenging issue in this study. It is 
questionable whether considering 10
th
 centile is able to distinguish pathological and 
physiological smallness of the fetuses effectively. Adding the findings of ultrasound scanning 
during pregnancy could increase the sensitivity and specificity of the birth weight centiles in 
definition of study groups. Moreover, heterogeneous pathophysiology of FGR is a 
challenging problem to achieve a similar profile of gene expression in different studies. In 
future work we aim to use measurement of % body fat at birth as a means of defining 
nutritionally under- and over-nourished cohorts more effectively. 
 
6.6 Future directions 
Although we have proven the value of these research methods in examination of placental 
gene expression, further work is needed to define the reliability of sample collection and 
processing after vaginal delivery. Time course analysis of RNA quality and optimisation of 
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the method would allow the work to be expanded to pregnancies delivering by labour as well 
as by Caesarean section. 
 
Different gene expression profiles observed in FGR and macrosomia need to be further 
validated by RT-PCR to achieve more robust results. Focussed experiments on specific 
pathways and networks, will discover molecular basis of fetal growth abnormalities and the 
possible role of these molecular changes in fetal programming. The possible link between 
intrauterine life and childhood or adulthood life is yet to be proven through comprehensive 
studies. 
 
Differentially expressed genes can be used for early detection of FGR and macrosomia before 
the establishment of irreversible pathophysiologic events and also for therapeutic purposes in 
the future. Further investigations are required to provide sufficient evidence for clinical use of 
these genes. 
 
6.7 Conclusion 
This study has shown that a significant number of genes are differentially expressed in the 
placentas of term fetuses that are affected by either fetal growth restriction or macrosomia. 
These genes are linked in a variety of developmental pathways that have a potential impact on 
fetal and childhood development. Important pathways that have been identified as been 
affected include those affecting embryonic development, angiogenesis, amino acid 
metabolism and the transmembrane transport of small molecules. Notch and p53 signalling 
pathways were also significantly affected in the placentas of fetuses that were growth 
restricted. These findings highlight the complex pathophysiology of fetal growth restriction. 
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In the macrosomic group, down-regulation of GCH1 which plays a role in umbilical cord 
formation and blood flow regulation together with LEP which plays a crucial role in energy 
homeostasis and control of food intake were noticeable. Considering the long term 
implications of leptin, this is an alarming issue for mothers and health service providers. 
Excessive fetal weight gain during intrauterine life might initiate some adverse consequences 
such as obesity, hypertension, and cardiovascular disease. 
 
The differential gene expression seen in these placental tissues suggest that both growth 
restricted and macrosomic newborns are susceptible to future health issues as a consequence 
of in-utero growth dysfunction. The concept that these differences could first be used to 
identify fetuses at risk of adverse obstetric outcome but could also be manipulated to improve 
short and long term health outcomes is attractive and deserves further attention. 
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